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BIOCOMPATIBILITY EVALUATIONS AND BIOMEDICAL SENSING 






Chair: Mark E. Meyerhoff 
Nitric oxide (NO) is a potent signaling molecule secreted by healthy vascular 
endothelial cells (EC) that is capable of inhibiting the activation and adhesion of platelets, 
preventing inflammation and inducing vasodilation.  Polymeric materials that mimic the 
EC through the continuous release or generation of NO are expected to exhibit enhanced 
biocompatibility in vivo.  In this dissertation research, the biocompatibility of novel NO-
releasing/generating materials has been evaluated via both in vitro and in vivo studies.   
A new in vitro platelet adhesion assay has been designed to quantify platelet 
adhesion on NO-releasing/generating polymer surfaces via their innate lactate 
dehydrogenase (LDH) content.  Using this assay, it was discovered that continuous NO 
fluxes of up to 7.05 ×10-10 mol cm-2 min-1 emitted from the polymer surfaces could 
reduce platelet adhesion by almost 80%.  Such an in vitro biocompatibility assay can be 
employed as a preliminary screening method in the development of new NO-
releasing/generating materials. 
 xii  
In addition, the first in vivo biocompatibility evaluation of NO-generating 
polymers was conducted in a porcine artery model for intravascular oxygen sensing 
catheters.  The Cu(I)-catalyzed decomposition of endogenous S-nitrosothiols (RSNOs) 
generated NO in situ at the polymer/blood interface and offered enhanced 
biocompatibility to the NO-generating catheters along with more accurate analytical 
results for intra-arterial measurements of PO2 levels. 
NO-generating polymers can also be utilized to fabricate electrochemical RSNO 
sensors based on the amperometric detection of NO generated by the reaction of RSNOs 
with immobilized catalysts.  Unlike conventional methodologies employed to measure 
labile RSNO, the advantage of the RSNO sensor method is that measurement in whole 
blood samples is possible and this minimizes sample processing artifacts in RSNO 
measurements.  An electrochemical RSNO sensor with organoselenium crosslinked 
polyethylenimine (RSePEI) catalyst was used to determine the endogenous RSNO levels 
in the whole blood of rabbits and pigs, and substantial variations of RSNO levels were 
found within the same animal species.  The photo-decomposition of RSNOs during 
sample collection was also studied.  The results show that complete insulation from 
external light during the blood sampling step is critical for the accurate determination of 
endogenous RSNOs. 









1.1. Overview and Scope of Areas Examined by this Thesis Research 
 
The development of reliable in vivo chemical sensors for real-time clinical 
monitoring of blood gases, electrolytes, glucose, etc. in critically ill and diabetic patients 
remains a great challenge owing to inherent biocompatibility problems that can cause 
errant analytical results upon sensor implantation (e.g., cell adhesion, thrombosis, 
inflammation) [1, 2].  Nitric oxide (NO) is a well-known inhibitor of platelet activation 
and adhesion, and also a potent inhibitor of smooth muscle cell proliferation [3].  In 
addition, NO mediates inflammatory response [4] and promotes angiogenesis [5].  
Polymers that release or generate NO at their surfaces have been shown to exhibit greatly 
enhanced thromboresistance in vivo when in contact with flowing blood [6, 7], as well as 
reduce inflammatory response when placed subcutaneously [8], and thus have the 
potential to improve the biocompatibility of implanted chemical sensors.  Locally 
elevated NO levels at the surface of implanted devices can be achieved by using 
polymers that incorporate NO donor species that can decompose and release NO 
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spontaneously when in contact with physiological fluids, or NO-generating polymers that 
possess an immobilized catalyst that decompose endogenous S-nitrosothiols (RSNOs) to 
generate NO in situ.  The structures of some endogenous RSNOs are illustrated in 
Figure 4.1. 
Although in vivo study remains the ‘gold standard’ for the determination of 
biocompatibility, in vitro biocompatibility assays are still an attractive approach for the 
sake of time and cost.  Therefore, it is the focus of this dissertation research to evaluate 
the biocompatibility of NO-releasing/generating biomaterials both in vitro and in vivo.  
Moreover, since RSNOs serve as substrates for the NO-generating polymeric materials, 
their endogenous concentrations are a critical factor in determining the biocompatibility 
of NO-generating materials.  However, there is lack of consensus regarding the 
endogenous concentrations of RSNO species in the literature.  The reported values 
range from nM to μM levels [9].  Thus, another goal of this dissertation research is to 
employ the new electrochemical RSNO sensors developed in the Meyerhoff lab to 
determine blood RSNO concentrations in various animals and to help provide insight 
regarding the potential function of NO-generating materials in vivo.     
 
1.2. Current Challenge to the Development of Implantable Chemical Sensors 
 
The care of critically ill hospitalized patients requires frequent and accurate 
measurements of arterial blood gases (pH, PO2, PCO2), electrolytes (Na+, K+, Ca2+) and 
glucose/lactate levels in undiluted whole blood.  To date, such values are usually 
obtained from in vitro tests using discrete blood samples drawn intermittently from 
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patients and analyzed on benchtop instruments or smaller point-of–care devices [2, 10, 
11].  However, intermittent sampling can miss events that can be life-threatening to the 
patient.  Indeed, isolated measurements are not able to provide the desired real-time 
monitoring of minute-to-minute physiological changes that can occur in unstable 
critically ill patients [2].  Therefore, continuous intravascular sensing of clinically 
important species would be of great value to improve the quality of health care for such 
patients.  
     At the same time, reliable in vivo monitoring of glucose concentrations in blood or 
the interstitial fluid could significantly enhance the quality of life for millions of 
non-hospitalized patients with diabetes mellitus. A successful implantable glucose sensor 
must: i) be small enough to be placed intravascularly or subcutaneously; ii) provide 
long-term stable analytical signals so that re-calibration can be minimized; iii) yield 
accurate measurements of glucose that correlate well with in vitro tests based on discrete 
blood samples so that therapeutic action can be taken based on the measured values (e.g., 
infusion of insulin); and iv) be compatible with the biological environment in which it is 
implanted (i.e., ‘biocompatible’). 
     Advances in the miniaturization of optical and electrochemical sensors for blood 
gases, electrolytes and glucose/lactate have made it possible to place such devices within 
blood vessels or under the skin.  However, despite significant efforts toward developing 
implantable intravascular and/or subcutaneous chemical sensors suitable for continuous 
in vivo monitoring, the routine clinical use of such devices has not yet been realized [1].  
The major challenge to be overcome for success in this area is the erratic analytical 
results obtained from sensors implanted in vivo.  Errant analytical results are generally 
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attributed to the adverse biological responses to such implanted devices [2, 11-13], which 
usually relates to the lack of biocompatibility of the implanted optical or electrochemical 
probes.  This problem has been reviewed previously [13].  Here, greater emphasis is 
given to a newer strategy involving coatings that generate nitric oxide (a species that can 
dramatically improve biocompatibility) from endogenous physiological species. 
The biocompatibility of an implantable medical device refers to the ability of the 
device to perform its intended function, with the desired degree of incorporation within 
the host, without eliciting any undesirable local or systemic effects in that host [14].  
The biological response to implanted sensors depends largely on the site of implantation.  
Intravascular placement is the most desirable for blood chemistry measurements.  The 
biocompatibility problems associated with sensors implanted intravascularly have been 
reviewed previously [1, 2, 10, 11].  When an intravascular sensor is in contact with 
blood, the initial biological response is the rapid adsorption of plasma proteins (e.g., 
fibrinogen, fibronectin and von Willebrand’s factor (vWF)) onto the surface, followed by 
the adhesion and activation of platelets (see Figure 1.1) [15].  Once activated, platelets 
undergo shape change and secretion of the granular contents.  The activated platelet is a 
key player in the coagulation cascade and will ultimately lead to the formation of a blood 
clot on the surface of the device [16].   
Such biofouling of the sensing membrane can restrict the diffusion of analyte to the 
sensor surface [17].  Moreover, the metabolic activities of adhered cells consume 
oxygen and glucose while producing carbon dioxide, thus changing the local 
concentration of blood gases and glucose levels sensed by the implanted device [13].   


























































intravascularly.  Even a monolayer of cells adhered onto the sensor surface is sufficient 
to produce the behavior illustrated in Figure 1.2.   
Similar patterns of deviation can also be observed when blood flow is reduced in 
the blood vessel where the sensor is placed, or when the sensor touches the wall of blood 
vessels where inherent metabolism of endothelial cells can affect sensor performance in 
the same way as adhered blood cells (“wall effect”) [2, 13].  Moreover, thrombus 
formation in patients can occur randomly since it also depends on factors such as the 
native coagulation propensity of a particular patient and the velocity of blood-flow within 
the lumen of the vessel in which the sensor is placed.  The unpredictability of 
intravascular sensor performance due to these biological factors makes the measurements 
unreliable, preventing timely therapeutic intervention. Sensors implanted under the skin 
(subcutaneous measurements), such as those often developed for monitoring glucose 
levels, do not encounter the same issues of platelet activation and thrombus formation.  
However, such sensors are subject to their own biocompatibility problems, primarily 
from inflammatory responses that can affect their accuracy.  The size, shape and 
physical/chemical properties of the implanted devices contribute to variations in the 
intensity and time duration of the inflammatory and wound-healing process [18].  Acute 
inflammatory response starts immediately after sensor implantation as fluids, plasma 
proteins and inflammatory cells migrate to the implant site [19].  The first event that 
occurs is protein adsorption, followed by the attack of phagocytic cells (neutrophils, 
monocytes and macrophages) to the implanted sensor, attempting to destroy it.  
However, since the sensor is large, only ‘frustrated phagocytosis’ occurs [18, 19].  Acute 









Figure 1.2.  Deviations in implanted sensor measurements of blood gases/pH due to cell 
adhesion and/or low blood flow at the implant site. 
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which are later replaced by macrophages, monocytes and lymphocytes during the chronic 
inflammation stage [19].  Ultimately, fibrous encapsulation of the subcutaneously 
implanted device by primarily macrophages and fibrin indicates the end-stage of the 
wound-healing process.  The fibrous capsule can change the analyte levels in the 
vicinity of the sensor through metabolic activities (e.g., faster glucose consumption).  It 
also can affect the transport of analyte to the sensor surface as well as that between the 
blood and the interstitial fluid.  This can lead to significant changes in the calibration 
curve (i.e., lowering the sensitivity) as well as affecting the lag time of the sensor’s 
response to the fluctuations of glucose levels in bulk blood for both optical [20, 21] and 
electrochemical sensors [12, 18, 22].  Angiogenesis around the site of tissue injury 
caused by implanted sensor is also part of the wound-healing process.  Since more blood 
vessels around the implanted sensors will facilitate the diffusion of the analyte from 
blood to the subcutaneous fluids (so interstitial fluid levels of the analyte more closely 
resemble blood levels), the degree of angiogenesis after implantation will also influence 
the output of sensors placed subcutaneously [23] 
 
1.3. Strategies for Improving Biocompatibility 
 
1.3.1. Surface Modifications 
The surface of an implanted device is thought by many to be of critical importance 
in determining the in vivo performance of any implant.  Surface modification strategies 
employed to address biocompatibility issues have been reviewed by Wisniewski et al. 
[17].  These approaches include hydrogel overlays, phospholipid-based biomimicry, 
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flow-based systems, Nafion coatings, surfactants, covalent attachments, diamond-like 
carbons, and topology treatments.  Surfaces with high water content are found to be 
more inert to protein adsorption and cell adhesion as a result of low interfacial energy 
[24].  Hydrogels and other hydrophilic surface modifications are aimed at minimizing 
protein adsorption, since such adsorption initiates a series of biological responses [15, 19].  
Biomaterials with the surface immobilized biological molecules, such as albumin [25], 
heparin [26], thrombomodulin [27], prostacyclin [28] and hyaluronic acid [29] have all 
been shown to exhibit some effectiveness in enhancing biocompatibility. 
 
1.3.2. Potential for Utilizing Nitric Oxide (NO) with In Vivo Sensors 
Unfortunately, hydrophilic surfaces by themselves may retard, but do not 
completely prevent the adsorption of proteins on artificial surfaces in vivo.  Eventually, 
the proteins that can initiate platelet adhesion/activation or those that mediate 
inflammatory responses will still adsorb onto the surface of the implanted sensor, leading 
to thrombus formation and/or inflammation.  The biological environments in which the 
sensors are implanted involve a myriad of activities besides the cell surface expression of 
certain molecules.  In the case of the vascular endothelium that lines the inner walls of 
all blood vessels (and is known to be the best example of a completely non-thrombogenic 
surface), a number of active molecules such as thrombomodulin, prostacyclin, heparan 
sulfate, and nitric oxide (NO) are either expressed at the surface or are continuously 
being secreted to mediate the biological responses underlining biocompatibility [16].  
Over the past twenty years, NO has received considerable interest from the 
pharmacological and biomedical research communities owing to its diverse physiological 
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functions as a protective, regulatory and signaling molecule involved in the regulation of 
blood pressure, clotting, neurotransmission and immune response.  Indeed, NO is 
widely recognized as a key anti-platelet, anti-inflammatory and vasodilating agent 
[30-34].  In addition, NO is also known to inhibit bacterial growth [35, 36] and promote 
angiogenesis [5]. 
Nitric oxide is produced endogenously from L-arginine and oxygen by enzymes 
known as nitric oxide synthases (NOS) [37].  NO exerts its vasodilation and anti-platelet 
function by binding to the heme iron of soluble guanylate cyclase and subsequently 
increasing the production and intracellular concentrations of cyclic guanosine 
monophosphate (cGMP), a secondary messenger [38].  The endogenous concentration 
of NO as a dissolved gas is very low (~3 nM) [39].  Under physiological conditions, 
oxidized NO (in the form of NO+ or N2O3) reacts with thiol groups in cysteine or 
cysteine-containing peptides and proteins (e.g., glutathione, albumin and hemoglobin) to 
yield S-nitrosothiols (RSNOs) [40, 41].  RSNOs act as carriers of NO in the body and 
are thought to be responsible for the storage and bioavailability of NO [39, 42] (see 
Section 1.5 below). 
Vasoconstriction can occur at the site where the intravascular sensor is implanted as 
a biological response to reduce bleeding at the implant site.  Meanwhile, platelets are 
activated and recruited to repair the vascular injury [43].  NO is synthesized in the 
endothelial cells that line the wall of healthy blood vessel and diffuses in all directions.  
When NO reaches the underlying vascular smooth muscle cells, NO stimulates cGMP 
production and, in turn, decreases the Ca2+ levels in the smooth muscle cells, leading to 
vascular relaxation [44].  Muscle relaxation allows the blood vessel to dilate and lowers 
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the blood pressure.  NO also diffuses into circulating platelets, especially when they 
approach the surface of the endothelium.  Platelet activation is also Ca2+ dependent [45] 
and is thus inhibited by NO [34, 46]. The lifetime of NO in whole blood is very short (< 1 
sec) due to its reaction with heme-containing compounds such as oxyhemoglobin [3].  
Therefore the anti-platelet effect occurs only locally when platelets are in close proximity 
to the endothelium, as the presence of red blood cells would block the NO transfer to 
platelets.  It has been estimated that the endothelial derived NO flux is in the range of 
0.5-4.0 ×10-10 mol cm-2 min-1 [47].  Therefore, if the surface of an intravascular sensor can 
release or generate NO at or above this range of fluxes, it is expected to display enhanced 
thromboresistance.  Furthermore, the released NO will be effective only locally at the 
blood/polymer interface, which is ideal for biocompatibility purposes.  Owing to the low 
NO fluxes, the small dimension of the intravascular sensor, and the very short half-life of 
NO in blood, the locally released NO is unlikely to cause any systemic effect that may 
lead to cytotoxicity or hemorrhage.   
Nitric oxide also is involved in virtually every step of the inflammatory process [4].  
In fact, NO plays a crucial role in wound healing and down regulates mediators of 
inflammatory response.  Low concentrations of NO can inhibit adhesive molecule 
expression, cytokine and chemokine synthesis as well as leukocyte adhesion and 
transmigration [4].  Nitric oxide also promotes angiogenesis and disruption of the 
NOS-based NO generation pathway is known to impair neovascularization [5].  
Subcutaneous implantation also brings the risk of infection, which can also be inhibited 
by NO [36].  Therefore, an active surface that can continuously release or generate NO 
in the interstitial fluid may also benefit greatly from a locally enhanced level of NO, with 
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respect to reducing inflammatory cell migration and promotion of neovascularization that 
could increase the exchange of glucose and other analytes into the subcutaneous fluid 
adjacent to the implanted sensor.  
 
1.4. Implantable Sensors with NO-Releasing/Generating Coatings 
 
1.4.1. NO-Releasing Materials 
Since the discovery of the anti-thrombogenic role of NO, the possibility of 
improving biocompatibility by incorporating NO-releasing/generating function into 
biomedical polymers has been explored by several research groups.  Ramamurthi and 
Lewis [46] used the direct infusion of gaseous NO(g) (0.1 ppm) through a semi-permeable 
membrane to produce surface NO fluxes ranging between 3-6.6 ×10-8 mol cm-2 min-1.  
These low levels of NO were shown to inhibit platelet adhesion by as much as 87%.  
However, it would be quite difficult to deliver gaseous NO (from a reservoir of NO gas) 
to the surface of an implanted sensor, once it was placed in an artery/vein or under the 
skin.  Fortunately, a number of NO donor compounds have been developed to deliver 
NO in vivo and study its biological effects [48].  For implantable sensor applications, the 
NO donors must be incorporated in the polymer either as a thin outer coating or into the 
bulk polymer from which the medical sensor is made (e.g., polymeric tubing for certain 
catheter style sensors).  The duration of NO release should match the implant lifetime of 
the device itself.  In addition, it is critical that the NO release rate be controllable, as 
excess exposure to the NO donor, NO and any reaction products can be cytotoxic, 
mutagenic or carcinogenic.  
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To date, the two most widely investigated NO donors for biomedical applications 
are S-nitrosothiols (RSNO) and N-diazeniumdiolates (so-called NONOates).  
S-Nitrosothiols can be prepared by reacting thiols with nitrous acid.  
S-Nitrosoglutathione (GSNO) and S-nitroso-N-acetyl-cysteine (SNAC) have been 
blended into various polymers (e.g., poly(vinyl alcohol), poly(vinyl pyrrolidone), 
poly(ethylene glycol)) by de Oliveira and coworkers for targeted delivery of NO and 
parent RSNOs [49-51].  Bohl and West demonstrated that S-nitrosocysteine (CysNO) 
immobilized within a poly(ethylene glycol) hydrogel reduced platelet adhesion and 
smooth muscle cell proliferation in vitro [52]. 
A N-diazeniumdiolate is an NO adduct with secondary amines [53].  One 
equivalent of amine reacts with two equivalents of NO to form the corresponding 
diazeniumdiolate under high NO(g) pressure (e.g., 80 psi).  The NO release from 
diazeniumdiolates is proton-driven and follows pseudo-first order kinetics at 
physiological pH [54].  Three general procedures have been used in the preparation of 
diazeniumdiolate-based NO-releasing polymers: 1) dispersion of small amine-based 
diazeniumdiolate molecules into polymer matrices (e.g., DBHD/N2O2) [55]; 2) 
diazeniumdiolation of covalently linked amine sites on pendant polymer side chains, or 
on the polymer backbone [56, 57]; and 3) covalent binding of diazeniumdiolate groups to 
micro- or nano-particles, and use of such particles as polymer fillers [58].  The half-life 
of NO release can be modulated by selecting different secondary amine structures [59] 
and the NO fluxes can be tuned by changing the diazeniumdiolate dopant amount or 
hydrophobicity of the polymer matrices or by applying topcoats of polymers to control 
the diffusion of water into the layer containing the NONOate.  The leaching of 
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non-covalently bound small molecule diazeniumdiolates can be greatly reduced by using 
highly lipophilic diazeniumdiolates blended into the polymer matrix [55].  The potential 
application of diazeniumdiolate-based NO release to implantable sensors has recently 
been reviewed [13]. 
A key assumption with respect to potentially using NO-release polymers to prepare 
implantable sensors is that the NO release chemistry should not interfere with the sensing 
chemistry of the device.  Since NO is a redox active species, it is necessary to establish 
that the initial NO donors and the released NO from the outer coating do not interfere 
with the analyte measurement by significantly changing the sensitivity, selectivity or 
lifetime of the implantable chemical sensor, especially electrochemical devices.  
Initial work with NO-releasing chemical sensors focused on using a small molecule 
NO donor, dimethylhexane diamine diazeniumdiolate (DMHD/N2O2), dispersed into 
plasticized poly(vinyl chloride) (PVC) and polyurethane (PU) membranes for the purpose 
of preparing NO-releasing potentiometric ion-selective sensors.  Indeed, Espadas-Torre 
et al. reported that pH and K+ sensors prepared with the NO-releasing polymer 
membranes (doped also with the appropriate ion-selective ionophores [tridodecylamine 
(TDDA) or valinomycin] for sensing purposes) exhibit similar potentiometric response 
sensitivities and selectivities towards H+ and K+ as control sensors without NO release 
[60].  The NO-releasing ion-selective polymer films also exhibit greatly reduced platelet 
adhesion and activation compared to control films without NO release when tested in 
vitro using platelet-rich sheep plasma.  Mowery et al. further demonstrated that two 
other NO donors, diazeniumdiolated linear polyethylenimine and diazeniumdiolated 
methoxymethylpiperazine PVC, can also be used to prepare potentiometric sensing 
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membranes [61].  They also extended the application of (DMHD/N2O2) to a Clark-style 
amperometric oxygen sensor and proved that NO release does not affect the sensor’s 
amperometric response [61].  Frost et al. utilized the diazeniumdiolated 
diaminoalkyltrimethoxylsilane (DACA/N2O2) crosslinked polydimethylsiloxane (PDMS) 
to coat the outer walls of a potentiometric CO2-sensing catheter [62].  The NO-releasing 
CO2 sensors exhibited comparable Nernstian response slopes as the control sensors 
without NO-release chemistry.  Apparently, the low fluxes of NO released from such 
coatings do not have a significant impact on the analytical performance of such devices.   
Nitric oxide release has also been employed to enhance the biocompatibility of 
optical sensors.  Schoenfisch et al. reported a dual-layer fluorescence-based oxygen 
sensor configuration with the underlying NO-releasing layer made from DACA/N2O2 
crosslinked silicone rubber (SR) covered by a second polymeric layer containing the 
pyrene/perylene fluorescent indicators [63].  The NO-releasing sensors yielded identical 
responses to oxygen as conventional sensors without NO release.  Further, Schoenfisch 
and coworkers developed a NO-releasing xerogel-based optical pH sensor and 
demonstrated its improved blood compatibility through an in vitro platelet adhesion study 
[64]. 
The initial proof-of-concept that NO release can improve the biocompatibility of 
devices implanted intravascularly was performed by implanting sham catheters coated 
with diazeniumdiolated methoxymethylpiperazine PVC into canine carotid arteries for 6 
h [61].  The catheters coated with NO-releasing polymer showed greatly reduced 
platelet activation and adhesion compared to conventional PVC implanted in the same 
animal. These experiments indicated that low levels of NO release did in fact inhibit 
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thrombus formation on the surface of implanted intravascular devices within the complex 
and dynamic environment of flowing blood. 
The first in vivo evaluation of NO-releasing intravascular chemical sensors was 
reported by Schoenfisch et al. [7].  In this study, DMHD/N2O2 dispersed in cross-linked 
silicone rubber (SR) was coated over the outer SR gas-permeable tubing of a Clark-style 
amperometric oxygen-sensing catheter to impart NO release.  These sensors were 
implanted in canine arteries for up to 23 h without systemic anticoagulation.  During the 
course of the experiments, the oxygen levels monitored by the NO-releasing sensors 
tracked more closely with in vitro blood gas analysis of PO2 levels performed on discrete 
blood samples drawn from the animal, as compared to non-NO release control oxygen 
sensors implanted within the same animal (i.e., more accurate results).  At the end of 
each animal study, the sensors were carefully explanted from the arteries and examined 
by scanning electron microscopy (SEM).  The NO-releasing catheters consistently 
showed a marked decrease in platelet adhesion under SEM, with no gross thrombus 
formation.  On the other hand, gross thrombus formation was routinely observed on the 
control catheters which were covered by adhered platelets, fibrin and entrapped red cells. 
These encouraging results suggested the potential of using NO-releasing polymers 
to enhance the biocompatibility and concomitant analytical performance of intravascular 
chemical sensors.  However, it was found that the small molecule NO donor 
(DMHD/N2O2) could leach out of the polymer coating and a significant amount of NO 
was released from the decomposition of the donor outside of the polymer coating matrix 
[65].  This poses potential risks as the decomposition product, free dimethylhexane 
diamine, could react with reactive nitrogen oxide species and form a N-nitrosamine, 
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which is carcinogenic.  In addition, the leaching of NO donor into the aqueous phase 
would reduce the effectiveness of locally released NO to inhibit platelet 
adhesion/activation at the polymer/blood interface (i.e., less NO being locally released at 
sensor/blood interface).   
To address the leaching problem, Zhang et al. developed the DACA-SR/N2O2  
material where the diazeniumdiolate groups are anchored on a diamine silane crosslinker 
and thus the leaching of the parent diamine from the polymer matrix is eliminated [66].  
Frost et al. applied this covalently attached diazeniumdiolated DACA-SR/N2O2 coating 
(~ 100 μm thickness) on the surface of Clark-style oxygen-sensing catheters and 
evaluated the performance of these devices in porcine carotid and femoral arteries for 16 
h [6].  The blood oxygen levels determined by the NO-releasing sensors (N = 9) were 
statistically identical to the standard in vitro blood gas measurements, while the control 
sensors (N = 9) implanted in the same animals showed statistically significant deviations 
(negative values) at 95% confidence interval in oxygen measurements after 10 h of 
implantation.  Furthermore, the NO-releasing catheters were found to be relatively 
thrombus-free after explantation, while the control catheters without NO-release 
exhibited largely varied degrees of biological response, ranging from very few adhered 
platelets to a complete coverage of the surface by blood clots.  Such variation in 
biological response is typically observed with implanted sensors, and it is precisely this 
variability that makes measurements with conventional sensors so unreliable.   
As mentioned above, another approach to the creation of NO release polymeric 
coatings is to use a more lipophilic parent diamine compound with longer alkyl 
side-chains so that extraction into the aqueous phase is minimized [55].  Replacing the 
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methyl side groups in DMHD with butyl groups enhances the partition coefficient of the 
diamine into the organic polymer phase by 104.  In another study, the resulting 
diazeniumdiolated dibutylhexyldiamine (DBHD/N2O2) was dispersed into SR, together 
with potassium tetrakis(4-chlorophenyl) borate (KTpClPB) which buffers the pH in the 
organic phase to maintain a more constant longer term NO release.  Biocompatibility 
evaluations of NO-releasing catheters with outer SR coatings containing DBHD/N2O2 in 
the porcine artery model yielded similar results to other NO-releasing sensor studies, with 
more accurate blood oxygen measurements and less platelet adhesion and activation 
observed [62]. 
NO-releasing polymers containing DBHD/N2O2 have also shown improved 
biocompatibility when used as outer coatings for preparation of needle-type subcutaneous 
glucose sensors.  Gifford et al. prepared glucose sensors with a thin PU/PDMS coating 
(~ 10 μm thick) doped with the DBHD/N2O2 NO donor and implanted them in rats 
together with control sensors [8].  Histological evaluation of neutrophil infiltration 
revealed that inflammatory response was greatly reduced during the first 24 h at implant 
sites where the NO release sensors were placed vs. control sites in the same animals.  
However, the NO release from the polymer coating could only last ca. 16 h, owing to the 
very thin coating necessary to prevent a dramatic decrease in the flux of glucose to the 
underlying glucose oxidase enzyme layer of the sensor.  Therefore, although the sensors 
remained functional in vivo for several days, the reduction of inflammatory response was 
not maintained for an extended implant period (3 d).  Increasing the coating thickness is 
not an option as it would change the membrane permeability and adversely affect the 
sensitivity and response time of the glucose sensor.  To circumvent the limitation of NO 
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donor reservoir in the NO-releasing coating, alternative NO-generating approaches have 
been pursued to immobilize catalysts onto the polymer surface that can decompose 
endogenous RSNOs, an NO carrier, to generate NO in situ at the polymer/blood interface. 
 
1.4.2. NO-Generating Materials 
As discussed above, polymer coatings containing NO donors on the surfaces of 
implantable sensors will eventually be depleted, and thus these sensors are likely to 
eventually lose the biocompatibility advantage offered by NO release.  The concept of 
“NO generation” coatings is to utilize the endogenous RSNO species that exist in the 
physiological fluids as a continuously replenishing NO donor to generate enhanced NO 
levels at the blood/polymer interface.  RSNOs are regarded as a reservoir and carrier of 
NO in the body [39, 67].  The most abundant endogenous RSNOs are S-nitrosoalbumin 
(AlbSNO) and GSNO.  Transnitrosylation reactions occur in vivo so that the 
nitroso-group can be transferred from one thiol to another [40, 42].  The cleavage of the 
S-NO bond in RSNOs to release NO can occur by three well-established mechanisms 
[68].  First, copper ion mediated catalytic decomposition requires Cu2+ to first be 
reduced to Cu+.  Copper(I) reacts with RSNO to release NO by transferring an electron, 
and thus forms a thiolate anion and regenerates Cu2+.  Under physiological conditions, 
ascorbate and thiolate anions are sufficient reducing agents to convert Cu2+ to Cu+.  The 
second RSNO decomposition pathway is through the reaction with high concentrations 
( > 1 mM) of ascorbate to release NO and produce thiolate and dehydroascorbate [69].  
The third decomposition mechanism of RSNOs is the homolytic cleavage of the S-NO 
bond by light at characteristic absorbance bands of 330-350 nm or 550-600 nm, yielding 
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NO and the disulfide of the parent thiols [70].  Further, Hou et al. reported that 
glutathione peroxidase (GPx) and other seleno compounds (e.g., selenocystamine) can 
also catalyze RSNO decomposition [71].  Recent research using organotellurium 
compounds indicate that they also possess similar catalytic activities towards RSNO 
decomposition [72]. 
The potential advantage of the NO-generation approach in vivo is the utilization of 
circulating RSNO as an unlimited supply of NO at the polymer/blood interface.  Duan et 
al. explored the possibility of generating NO by transnitrosation from endogenous 
RSNOs to L-cysteine immobilized on polymer surfaces [73].  They covalently attached 
L-cysteine to PU and polyethylene terephthalate (PET) and these L-cysteine modified 
polymers reduce in vitro platelet adhesion by more than 50% when tested in plasma, but 
not with platelet suspension in phosphate buffer.  The suggested mechanism was 
through the transnitrosation of NO+ from endogenous RSNOs (e.g., AlbSNO) to the 
cysteine moiety on the polymer surface to yield immobilized CysNO.  CysNO is 
relatively unstable and can thus decompose to release NO locally at the polymer 
interface. 
Oh et al. developed a lipophilic Cu(II)-cyclen type complex to generate NO from 
RSNO and nitrite under physiological conditions [74, 75].  PVC and PU films doped 
with this Cu(II) complex generated NO in the presence of reducing agents (e.g., ascorbate, 
cysteine, glutathione).  It was demonstrated such polymers can generated NO with an 
apparent surface flux as high as 8 ×10-10 mol cm-2 min-1 from physiological levels (1 μM) 
of GSNO.  The same polymer was also shown to generate NO from nitrite under 
physiological conditions in the presence of ascorbate.  A material that is capable of 
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locally and continuously generating NO from endogenous RSNOs and nitrite could be 
used to tackle the biocompatibility problems for not only implantable sensors, but even 
long-term implants, such as stents and vascular grafts. 
Besides the Cu-cyclen complex, any other form of Cu that can provide Cu2+ or Cu+ 
cation could also serve as the catalyst to generate NO at the polymer/blood interface.  
Further, it was recently discovered that organoselenium compounds and selenium 
containing proteins (e.g., glutathione peroxidase) are also capable of generating NO from 
RSNOs [71].  In Chapter 3 of this thesis, metallic copper particles (micron- or 
nano-sized) are loaded into the polymer coatings on the Clark-style intravascular 
oxygen-sensing catheters as a proof-of-concept study on NO-generating coatings for 
implantable sensors with enhanced biocompatibility. 
 
1.5. Determining Endogenous RSNO Levels 
 
The successful biomedical application of the NO-generation approach depends 
largely on the knowledge and control over the endogenous levels of RSNOs in blood.   
Indeed, the question of actual blood RSNO levels is still the center of considerable debate 
[76] and the reported normal values in the literature range from 15 nM to 7 μM [39, 77] 
for a number of reasons.  The labile nature of the RSNO compounds, which can be 
easily decomposed by light, heat or trace metal ions [68], the difference in sample 
handling and analytical procedure employed, and the ease with which RSNOs, NO and 
their metabolites (e.g., nitrite and iron-nitrosyl) can react with blood components to give 
either false positives or false negatives [78-80], all add to the complexity of the accurate 
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determination of RSNOs in blood.  Most of the methodologies that detect RSNOs in 
blood require complicated sample treatment which may introduce artifacts in subsequent 
measurements [76].  Therefore, a method to quickly measure RSNO with minimal 
sample preparation is surely needed.   
Recently, Cha et al. reported electrochemical RSNO sensors with Cu- or Se-based 
catalysts immobilized at the distal tip of an NO electrode [81, 82].  A schematic of the 
Se-based RSNO sensor and the Se-functionalized poly(ethylenimine) (Se-PEI) is shown 
in Figure 1.3.  When used with a control NO sensor (without Se-PEI), such RSNO 
sensors enable the rapid detection of RSNOs in whole blood at the bedside.  Moreover, 
the Se-based RSNO sensor possesses almost equal sensitivity towards all low molecular 
weight RSNO species tested, rendering it potentially suitable to assess the ‘global’ RSNO 
concentrations in whole blood.  Even within the same species, a substantial variation in 
endogenous RSNO concentrations may exist between individual subjects, giving rise to 
the difference in biological response to the NO-generating medical devices.  To 
overcome the limitation of basal RSNO levels, it might be necessary to provide a bolus of 
a naturally occurring RSNO at certain intervals, or better yet to continuously infuse 
RSNOs intravenously to maintain blood RSNO levels that are sufficient to generate 


























Figure 1.3. (a) Schematic of the RSe-PEI based RSNO sensor; (b) structure of the 
RSe-PEI catalyst.  
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1.6. Statement of Dissertation Research 
 
The primary goal of this dissertation research is to develop evaluation techniques to 
determine the biocompatibility of the novel NO-releasing/generating polymeric materials 
that can ultimately be employed to prepare more biocompatible in vivo chemical sensors.  
Further, as the endogenous RSNO species play a pivotal role in the biocompatibility of 
new NO-generating materials, efforts are dedicated herein to examine the interaction 
between NO-generating materials and the blood RSNO levels by means of an 
electrochemical RSNO sensor based on organoselenium catalyst. 
For in vitro biocompatibility evaluation of polymeric materials, platelet adhesion 
studies via scanning electron microscopy (SEM) or radioactive labeling of platelets, have 
traditionally been employed [60, 65, 83].  However, the SEM approach only examines a 
tiny fraction of the entire surface and therefore is unable to provide quantitative 
information about adhered platelets.  The radio-labeled platelet method, on the other 
hand, suffers from the possible activation of platelet during the labeling step and thus 
might not indicate the true thrombogenicity of the material being tested.  To assess the 
biocompatibility of NO-releasing polymers and determine the optimal NO flux for 
biomedical applications, a quantitative and reliable in vitro platelet adhesion assay is 
desirable.  In Chapter 2, a new in vitro platelet adhesion assay for 
NO-releasing/generating polymers is described based on quantification of the lactate 
dehydrogenase (LDH) content of adhered platelets.  Reduced platelet adhesion was 
found to correlate with the increase in NO fluxes emanated from NO-releasing polymers.  
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Platelet adhesion was effectively reduced from 14.0±2.1 ×105 cells cm-2 on the control 
polymer to 2.96±0.18 ×105 cells cm-2 on polymers with an NO flux of 7.05±0.25 ×10-10 
mol cm-2 min-1.  
The first in vivo biocompatibility evaluation of NO-generating materials will be 
presented in Chapter 3.  In this study, metallic Cu0 particles (3 μm or 80 nm) are 
incorporated into the polymeric coatings on the surface of a Clark-style intravascular 
oxygen-sensing catheter to serve as the NO-generating catalyst.  Such NO-generating 
sensors were implanted into porcine arteries together with control sensors without the 
NO-generating capability for up to 20 h.  Overall, the NO-generating sensors (N=12 for 
the 3-μm group and N=6 for the 80-nm group) showed improved biocompatibility along 
with more accurate PO2 measurements when compared to control sensors without Cu0 
particles.   
The successful function of the NO-generating materials requires the knowledge and 
control of endogenous RSNO concentrations.  The study of baseline blood RSNO levels 
and their changes in the presence of NO-generating materials, by means of the 
electrochemical RSNO sensor, will be described in Chapter 4.  This includes the 
fundamental aspects of the sensing mechanism, as well as the applications of RSNO 
measurements in a number of rabbits, pigs and human subjects.  A key discovery in this 
study is that proper sampling of blood is critical to avoid photolytic decomposition of 
endogenous RSNO species. 
Chapter 5 provides a summary of the results obtained and offers suggestions for 
future research directions based on the findings of this dissertation research. 
Finally, it should be noted that this dissertation is prepared on the basis of multiple 
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manuscripts.  All the chapters, except Chapter 5, are adapted from either published 
articles or manuscripts to be submitted for publication.  The majority of the content of 
this Chapter 1 is in press for the ‘Special Issue on Remote Chemo/Bio-Sensing’ in 
Talanta.  The LDH assay on NO-releasing polymers described in Chapter 2 has been 
published as a full paper in the Journal of Biomedical Materials Research, A (2007) [84].  
Chapter 3 is converted from a full paper published in the 25th Anniversary Issue of 
Sensors and Actuators B, Chemical (2007) [85].  The results of endogenous RSNO 
measurements in rabbit blood from Chapter 4 will be prepared into a manuscript intended 
for publication in Analytical Chemistry.  The photo-instability of RSNOs discussed in 
Chapter 4 will be addressed separately in a letter to the editor of Clinical Chemistry.  
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IN VITRO PLATELET ADHESION ASSAY FOR NITRIC OXIDE-
RELEASING/GENERATING POLYMERS VIA 





Nitric oxide (NO) is now widely recognized as a potent inhibitor of platelet adhesion 
and activation [1, 2], as well as a naturally occurring vasodilator [3].  In fact, the 
extraordinarily thromboresistant nature of the inner walls of blood vessels is, in part, due 
to the continuous production of NO by the endothelial cells that line such vessels [4, 5].  
The NO flux from the endothelium is estimated to be in the range of 0.5 - 4.0 ×10-10 mol 
cm-2 min-1 [4].  Previous studies based on the discrete infusions of NO donors into blood 
suggested that higher NO levels produced from such donors exert greater antiplatelet 
activities [6-8].  However, these experiments failed to simulate the function of a healthy 
endothelium, which produces a low but continuous flux of NO from its surface.  Another 
report by Ramamurthi and Lewis using flowing platelets in a membrane-based diffusion 
device demonstrated that platelet adhesion to a collagen-coated membrane (using 
radiolabelled platelets) was inhibited by very low fluxes of NO but leveled off as higher 
NO concentrations were used [9].   
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Research in this lab [10-20] and elsewhere [21, 22] has been aimed at preparing 
more biocompatible polymeric coatings that continuously produce NO at physiological 
levels to mimic the function of the healthy endothelium, thus creating non-thrombogenic 
surfaces.  The continuous production of NO at polymer/blood interfaces can be achieved 
by two methods—either by doping the polymer with NO donors that can spontaneous 
release NO (i.e., NO-releasing polymers), or by impregnating the polymer with catalysts 
that react with endogenous NO precursors (e.g., S-nitrosothiols) to generate NO in situ at 
the polymer/blood interface (i.e., NO-generating polymers).  Indeed, a growing number 
of reports have already demonstrated the improved blood compatibility of NO-
releasing/generating polymeric materials using in vivo animal model studies [10-15, 23].  
It has also been  reported that discrete additions of NO or its donor species  (e.g., 
diazeniumdiolates, nitrosothiols, etc.) can inhibit platelet adhesion and activation in vitro 
[6-8, 24-26].  However, there is a lack of a simple and reliable in vitro method to assay 
the platelet adhesion on polymers that continuously release or generate NO, and to assess 
how varying levels of NO release effect platelet adhesion.  Such a method would be 
attractive to carry out preliminary biocompatibility studies of any new NO-
releasing/generating polymers, such as determining the required NO flux and 
donor/catalyst amounts, before undertaking more expensive in vivo testing. 
The two most commonly used in vitro platelet adhesion assays are scanning 
electron microscopy (SEM) [27] and radioisotope-labeled platelet counting [28]. 
However, both methods have their own drawbacks that render them unsuitable for 
quantitative assay. SEM only studies a very small fraction of the total surface that had 
been in contact with platelets, of which the ‘representativeness’ of the selected viewing 
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areas is always questionable. Radio-labeling, on the other hand, suffers from the potential 
for pre-activation of platelet as a result of the labeling step. 
In recent years, the assay of lactate dehydrogenase (LDH) present in platelets has 
been reported to provide a useful approach to study in vitro platelet adhesion on 
chemically and/or physically modified surfaces [29-33].  LDH is normally stored within 
intact platelets and other blood cells.  Elevated serum LDH levels are usually associated 
with cytolytic events [34].  When platelets adhered to polymer surfaces are lysed using a 
surfactant solution, the amount of LDH released into the bulk solution is proportional to 
the number of cells adhered.  The activity of LDH can be measured by a simple 
colorimetric assay and used to quantify platelet adhesion.  In this chapter, the use of an 
LDH assay is reported to study the efficacy of varying levels of NO, a bioactive species, 
released from poly(vinyl chloride) (PVC) films doped with a lipophilic diazeniumdiolate 
type NO donor, in reducing platelet adhesion onto the surface of such polymeric 
materials.  It will be shown that increasing fluxes of NO release decrease the observed 
platelet adhesion.  Such an LDH assay is also utilized to study platelet adhesion on NO-
generating polymers with a lipophilic Cu(II)-cyclen type catalyst, where no statistically 
significant differences were found between the NO-generating and control polymers.  
Possible reasons for this observation will be discussed in Section 2.3.5. 
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2.2.  Materials and Methods 
 
2.2.1. Preparation of NO-Releasing Polymer Coatings 
Poly(vinyl chloride) (average MW = 106,000, Aldrich, Milwaukee, WI) was mixed 
with sebacic acid di(2-ethylhexyl) ester (DOS, Sigma, St.  Louis, MO) in dry 
tetrahydrofuran (THF, Fisher Scientific, Pittsburgh, PA) to make a solution containing 
2% (w/v) PVC and 2% (w/v) DOS.  For control films, N,N’-dibutyl-1,6-hexanediamine 
(DBHD, Aldrich) was mixed with potassium tetrakis(4-chlorophenyl)-borate (KTpClPB, 
Fluka, Buchs, Switzerland) in a 1 : 1 molar ratio and dispersed in the polymer solution to 
yield 4 wt% of DBHD in the final cured polymer film.  The NO adduct, DBHD/N2O2 
(diazeniumdiolated DBHD) was synthesized as previously reported [10].  DBHD/N2O2 
and equal molar KTpClPB were dispersed into the polymer casting solution in a similar 
manner as the control film to yield 0.50, 1.0, 2.0 and 4.0 wt% of final DBHD/N2O2 
loading.  The coating cocktails were sonicated for 15 min and then 0.25 mL aliquots were 
placed in a well of 96-well round-bottom polypropylene microtiterplates (Evergreen 
Scientific, Los Angles, CA).  The polymer film was allowed to cure under ambient 
condition over night before a 3 μm layer of plain PVC/DOS (1:1) was applied as a 
topcoat.  The resulting polymer films were allowed to cure for another 24 h before use. 
 
2.2.2. NO-Release Measurement 
Nitric oxide released from the different polymer-coated wells was measured via a 
chemiluminescence NO AnalyzerTM (NOA), Model 280 (Sievers Instruments, Boulder, 
CO), to assess the NO-release profile and to determine the optimal time window for 
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platelet adhesion studies.  The entire polymer-coated well was immersed in phosphate 
buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10 mM sodium phosphate, pH 7.4) at 
37 ºC and the solution was bubbled with N2.  NO released from the polymer coating 
within the well was purged from the buffer, carried by the N2 gas into the 
chemiluminescence reaction chamber of the instrument, and monitored in real-time.   
 
2.2.3. Platelet Adhesion Studies 
Arterial blood from New Zealand white rabbits, weighing 2.5 - 3 kg, was drawn 
into 9:1 volume of blood : anticoagulant citrate/phosphate/dextrose solution (Abbott 
Labs, North Chicago, IL) containing 15.6 mM citric acid, 89.5 mM tribasic sodium 
citrate, 16.1 mM NaH2PO4 and 128 mM dextrose.  NIH guidelines for the care and use of 
laboratory animals (NIH Publication #85-23 Rev. 1985) were observed throughout.  The 
citrated whole blood was centrifuged at 110 ×g for 15 min at 22ºC.  Platelet-rich plasma 
(PRP) was collected from the supernatant.  To re-establish platelet activity, CaCl2 was 
added to the PRP to raise [Ca2+] by 2 mM.  Before PRP incubation, the polymer-coated 
microtiter plate wells were pre-hydrated by incubating with 200 μL PBS for 3 h at 37 ºC 
to achieve the optimal NO fluxes.  The PBS solution was removed after this pre-
incubation period.  Then, 100 μL of re-calcified PRP was added to each polymer-coated 
well and incubated for 1 h at 37 ºC under static conditions.  The PRP was then decanted 
and the wells were washed once with 200 μL PBS.  The entire duration from blood 
collection to the conclusion of the platelet adhesion step was less than 3 h.   
 
2.2.4. LDH Assay 
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Adhered platelets were lysed using a lysing buffer which was PBS plus 1% (w/v) 
Triton X-100 (Sigma) and 0.75% (w/v) bovine serum albumin (Sigma).  One hundred 
and fifty μL of lysing buffer was incubated in each well for 1 h at 37 ºC with occasional 
agitation to completely disrupt the platelet membranes.  Then, 100 μL of each lysate 
solution was pipetted into wells of a second 96-well polystyrene microtiter plate (Fisher) 
that contained 100 μL of reagent from an LDH assay kit (Roche Applied Sciences, 
Indianapolis, IN).  Absorbance of each well at 490 nm was monitored for 1 h by a 
Labsystems Multiskan RC microplate reader (Fisher).  The slopes derived from the initial 
linear portion of the absorbance vs. time curves were used for LDH quantification.   
Blank experiments were performed in a similar manner.  Briefly, free LDH from 
rabbit muscle (Roche Molecular Biochemicals, Mannheim, Germany) was dissolved in 
the same lysing buffer at 3 mU/mL.  Then, 150 μL of this free LDH solution was placed 
in polymer-coated wells that had been previously hydrated with PBS buffer for 3 h to 
establish relatively stable NO release fluxes.  The wells were further incubated with the 
LDH solution for 1 h at 37 ºC.  In this way, the free LDH would have the same duration 
of exposure to the same NO flux as the LDH originating from adhered platelets.  The 
activity of the free LDH was assayed in an identical manner as the LDH in the lysate 
solutions. 
 
2.2.5. Platelet Counting and LDH Calibration 
Platelet rich plasma, obtained as described above, was further centrifuged at 1500 
×g for 15 min to produce platelet-poor plasma (PPP) and a platelet pellet.  The 
supernatant PPP was carefully removed and the pellet of platelets was gently resuspended 
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in Tyrode’s buffer (137 mM NaCl, 95 mM NaHCO3, 1.8 mM CaCl2, 1.0 mM MgCl2, 2.7 
mM KCl, 0.4 mM NaH2PO4 and 5 mM D-glucose).  The platelet number in this 
suspension was counted by a Z1 Coulter particle counter (Beckman-Coulter, Miami, FL).  
Varying volumes of the platelet suspension derived from the pellet were also placed in 
the lysing buffer and incubated at 37 ºC for 1 h to completely release the LDH content of 
the platelets.  Then, 100 μL of each sample was mixed with equal volume of the LDH 
assay kit reagent in polystyrene microplate wells and assayed for LDH activity.  The 
slopes obtained were used to construct the calibration curve of LDH activity versus 
platelet number, based on the Coulter counter measurement of the original stock platelet 
suspension in cells/ml. 
 
2.2.6. SEM Analysis 
Scanning electron microscopy (SEM) images for surfaces of the various polymeric 
films were obtained in addition to the LDH assays.  After PRP incubation, adhered 
platelets in some wells were fixed with 4% glutaraldehyde (Sigma) for 1 h and then 
dehydrated in a series of ethanol solutions and dried overnight [13].  The bottom 
hemisphere was cut, sputter-coated with gold and examined by a Hitachi S-3200N 
scanning electron microscope. 
 
2.2.7. Preparation, Characterization and Platelet Adhesion Studies of NO-
Generating Polymers 
A lipophilic Cu(II)-cyclen analog, Cu(II)-dibenzo-[e,k]-2,3,8,9-tetraphenyl-
1,4,7,10-tetraaza-cyclododeca-1,3,7,9-tetraene (Cu-DTTCT), was prepared by a 
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previously reported method [35].  Cu-DTTCT was dissolved in dry THF and mixed with 
THF solutions of PVC, 2-nitrophenyl octyl ether (NPOE, Fluka) and/or DOS to yield 
polymer solutions of 2% (w/v) PVC and 2% (w/v) plasticizer (i.e., NPOE or DOS) 
containing various amounts of Cu-DTTCT (2 or 5 wt% in the final cured polymer).  Two 
hundred and fifty μL of the polymer solution was loaded into each well of a 96-well 
polypropylene microtiter plate and allowed to cure over night before vacuum drying for 
24 h.  The control polymer film was prepared by substituting Cu-DTTCT with 
unmetallated DTTCT ligand and cured in the same way as described above. 
To determine the NO-generation, the polymers were dip-coated onto glass-slides, 
dried in the same manner and then placed in the NOA cell containing 2 mL PBS, 5 μM S-
nitrosoglutathione (GSNO, prepared fresh via a reported method [36]), 30 μM reduced 
glutathione (GSH, Sigma) and 10 μM EDTA at 37 ºC.   
For the platelet adhesion study, rabbit blood was drawn into a syringe with 5 U/cc 
sodium heparin (Baxter, Deerfield, IL) and centrifuged as in Section 2.2.3. to obtain PRP.  
The platelet number was counted by the method described in Section 2.2.5.  One hundred 
μL of PRP was incubated at 37 ºC for 30 min in either NO-generating or control wells.  
Five μM GSNO was supplemented to one half of the NO-generating and control wells.  
The PRP was later removed and the wells were washed once with 200 μL PBS.  The 
assay for LDH content followed the same procedure outlined in Section 2.2.4. 
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2.3.  Results and Discussion 
 
2.3.1. NO-Releasing Polymer Coatings 
By using a microtiter plate with rounded well bottoms, a polymer coating of 
relatively consistent thickness can be achieved.  The coating method described in the 
Experimental Section yields a 1.74 cm2 polymer film with ca. 60 μm thickness as 
determined by an optical microscope.  Addition of KTpClPB to the underlying layer of 
the plasticized PVC film helps to achieve a more stable NO flux by maintaining charge 
neutrality and a constant pH within the polymer phase as the DBHD/N2O2 species 
releases NO and creates excess amine sites in the form of DBHD [10].  The NO release 
from DBHD/N2O2 decomposition can occur via two mechanisms, proton-driven [37] or 
thermal dissociation [10].  In this experiment, temperature was maintained at 37 ºC, 
except for the final assay of LDH on the microplate reader.  Further, the pH of all 
solutions, including the anticoagulated PRP, was kept at pH 7.4 for the precise 
manipulation of NO fluxes. 
  All of the DBHD/N2O2 doped polymer films exhibited continuous NO release for 
over 24 h.  However, maximum NO fluxes were typically observed between 2 - 5 h after 
wetting and the overall magnitude of NO fluxes for the films was proportional to the 
amount of DBHD/N2O2 doped within the underlying polymer layer.  The typical NO 
release profiles for the coatings over the first 8 h are shown in Figure 2.1(A) for films 
doped with 0 - 4 wt% DBHD/N2O2 (and equal moles of KTpClPB).  It is obvious that the 
NO flux decays significantly for the film with the highest NO donor loading (4 wt%), 




Figure 2.1.  (A) NO flux profiles for polymer-coated wells doped with 0.50, 1.0, 2.0 and 
4.0 wt% DBHD/N2O2 and equimolar KTpClPB.  (B)Average NO fluxes and 
S.D. during the 3-4 h time window for each DBHD/N2O2 loading. N = 4 for 
each loading.   
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are conducted during a period of relatively constant NO flux, the time window between 3 
- 4 h was selected for the platelet studies for all polymer film compositions examined.  
Figure 2.1(B) shows the statistics for the average flux levels at each DBHD/N2O2 
concentration (N = 4 films).  Average fluxes during this period for the four different 
loadings were 0.93(± 0.07), 1.69(± 0.19), 3.59(± 0.17), and 7.05(± 0.25) ×10-10 mol cm-2 
min-1, respectively.  Higher DBHD/N2O2 loadings (e.g., 8 wt%) were also tested.  They 
yielded fluxes of over 10×10-10 mol cm-2 min-1.  However, the polymer surfaces become 
much rougher in this case, as determined by SEM.  This is likely due to the poor 
solubility of DBHD/N2O2 in the polymer matrix and therefore the surface roughness 
becomes more pronounced as the DBHD/N2O2 concentration goes above 4 wt%.   
 
2.3.2. Platelet Adhesion 
Unlike radioactive labeling of platelet, the major advantage of the LDH assay is its 
simplicity, which minimizes possible activation of resting platelets.  Hence it has the 
potential to be more reproducible.  This attribute is critical for the evaluation of 
potentially more biocompatible materials.  Platelet adhesion experiments were repeated 
using three different lots of blood (from different animals) and the results were found to 
be quite reproducible.  During the initial incubation step, PRP was in contact with 0.834 
cm2 of polymer surface in each well.  This surface area was thus used to calculate the 
average platelet density on the films after determining LDH activity.  However, it should 
be noted that the platelet coverage was not even over the entire surface of the polymer 
films (as determined by SEM), likely owing to the hemispherical shape of the wells.  No 
fixation was used after platelet adhesion since platelets fixed with the common fixative, 
41 
glutaraldehyde, exhibited no LDH activity in the subsequent assay.  Therefore, the 
unfixed platelets were loosely adhered to the polymer surfaces.  Rinsing the wells three 
times yielded near-baseline LDH activities across all polymers tested, probably because 
of the removal of adhered platelets.  In the final protocol, the wells were washed only 
once after platelet incubation, which was found to be sufficient to distinguish the extent 
of platelet adhesion as a function of NO flux.   
 
2.3.3. LDH Assay 
Prior to testing the effect of NO with respect to platelet adhesion, it was necessary 
to establish that NO has no effect on LDH activity.  As a free radical, NO is known to 
react with various enzymes, which could possibly change their function and efficacy in 
catalysis [38, 39].  Previous studies using the LDH assay to assess the  biocompatibility 
of polymers involved evaluating only physically [31, 33] or chemically [30, 32] modified 
surfaces, not a material that releases a reactive species such as  NO.  Consequently, it was 
crucial to verify that any ‘observed’ reduction in LDH activity derived from experiments 
using PRP was indeed the results of less adhered platelets rather than any inhibition of 
LDH function in the presence of continuous NO production.   
An appropriate blank experiment was performed to evaluate the influence of 
continuous NO release on LDH activity.  The enzyme concentration was set at 3 mU/mL 
since this was the level typically seen for the control experiments (after cell lysis) with 
platelets.  Table 2.1 lists the free LDH activity in the control and DBHD/N2O2 load wells, 
as well as the blank with only plain 1:1 PVC/DOS films and no other additives.  














Composition Blank Control 0.5% 1% 2% 4% 
% LDH 100.0 89.7 103.6 98.1 98.9 93.3 





Table 2.1.  Free LDH activity after 1 h incubation in blank (plain PVC/DOS), control and 
various NO-releasing polymer-coated wells, as determined by colorimetric 
reaction rate.  LDH activity was set to 100% in blank polymer wells and 




activity also decreases with higher NO donor loading in the polymer films.  Since LDH 
has an iso-electric pH value (pI) of 4.6, it will be negatively charged in the PBS buffer.  
Thus, electrostatic interaction with the positively-charged surface of the polymers is a 
possible explanation for the data shown in Table 2.1.  The control polymer has the 
highest concentration (4 wt%) of free amine (DBHD) which will gradually become 
protonated to create a positively charged surface (as it diffuses into the top coat layer of 
plain PVC polymer).  Once LDH is attracted to polymer surface, less free LDH will be 
measured in the bulk solution, hence giving a false-negative result.  
In the case of the NO-releasing polymers, the amine will also be formed upon 
hydrolysis of the diazeniumdiolate [37].  However, at the time of assay, the 
diazeniumdiolate is not 100% hydrolyzed and therefore amine sites in NO-releasing 
polymers will be fewer compared to those in the control.  Because of this difference in 
amine site density between the diazeniumdiolated and non-diazeniumdiolated DBHD, the 
false negatives cannot be simply corrected by simultaneously collecting the LDH 
activities from same wt% control and DBHD/N2O2 loaded polymer films.  Even though a 
top coat was applied and bovine serum albumin was added to the lysing buffer to 
minimize nonspecific adsorption of LDH to the surface of the polymers, it cannot be 
completely eliminated.  This false-negative result from the control polymers suggested 
that the actual LDH levels in control polymer coated wells could be ~ 10% higher than 
that measured from this LDH assay (see below).  
Basal LDH present in plasma could also adsorb onto the polymers and contribute to 
a common baseline across all polymers tested.  It has been reported that PRP contains 
significant LDH activity and that LDH activity can be detected on polymer surfaces 
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incubated with PPP [29].  This adsorbed LDH may later be desorbed during the cell 
lysing stage and contribute to total LDH activity in this assay.  To prove this, PRP was 
replaced by PPP in the platelet adhesion step, followed by identical washing, lysis and 
assay procedures.  The baseline LDH level in PPP was found to be equivalent to a 
platelet density of ca. 1.00 (±0.25) ×105 cm-2 on all polymers.  This baseline was not 
subtracted from the platelet adhesion results, since there could be more cytolysis in a 
given preparation of PPP (as it was prepared by centrifugation at a much higher RCF than 
PRP) that can give rise to a higher serum LDH level.  However, the presence of this 
background LDH activity derived from the plasma suggests an even greater reduction, 
percentage-wise, of adhered platelets on NO-releasing polymers for the experiments 
described below.   
As shown in Figure 2.2, progressively fewer platelets adhered on polymer surfaces 
as the NO flux increases.  The control polymer has an apparent platelet density of 14.0 
(±2.5) ×105 cm-2, while the 0.5%, 1%, 2% and 4% DBHD/N2O2 doped films reduced the 
platelet density to 7.06 (±1.0) ×105 cm-2, 4.82 (±0.79) ×105 cm-2, 4.16 (±0.68) ×105 cm-2 
and 2.96 (±0.21) ×105 cm-2, respectively (N = 12 for all experiments, using at least 3 
different blood lots as the source for the PRP).  In all cases, platelet adhesion on the NO-
releasing polymers is statistically different from the control (p < 0.0001).  The influence 
of LDH adsorption via the mechanisms discussed above is insignificant as compared to 
the great reduction of LDH activities on NO-releasing polymer surfaces.   
Polymers with higher DBHD/N2O2 loadings (i.e., 8, 12 and 16 wt%) have also been 
tested in the above manner.  Bearing in mind DBHD/N2O2’s poor solubility in these 










Figure 2.2.  Platelet adhesion density on control and various DBHD/N2O2 loaded 




surfaces despite the fact that the NO fluxes are even higher.  Indeed, another in vivo 
model with DBHD/N2O2 coated on the inner walls of rabbit extracorporeal circuits 
provided similar results – with an intermediate level of DBHD/N2O2 loading yielding the 
best biocompatibility [40].  However, such results do not necessarily suggest the inability 
of NO as an inhibitor of platelet adhesion and activation at those higher fluxes.  Should a 
new lipophilic NO donor be developed in the future than can provide smoother surfaces 
while still maintaining the desirable properties of DBHD/N2O2, such as minimal donor 
leaching and a wide range of attainable NO fluxes, the effect of platelet inhibition by NO 
fluxes higher than those tested herein could be explored. 
 
2.3.4. SEM Analysis 
To verify the results obtained from the LDH assay, SEM images were taken from 
the control and 4% DBHD/N2O2 doped films.  The SEM micrographs shown in Figure 
2.3 were taken at the center of the well bottoms.  It is obvious that platelets on NO-
releasing surfaces were much less activated compared with those on the control surface.  
Also, there were far fewer platelets per viewing area on NO-releasing surfaces.  
However, SEM does not serve as a quantitative measure since the surface it examines 
constitutes only a tiny portion of the total surface in contact with platelet-rich plasma.  
This is the reason why the LDH assay was used to evaluate average platelet adhesion 
over the entire surfaces.   
 










Figure 2.3.  SEM micrographs of adhered platelets on control polymers (a, b) and 4 wt% 
DBHD/N2O2 loaded polymers (c, d) after 1 h PRP incubation. 
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Heparin was used instead of citrate as the anticoagulant in experiments involving 
Cu-DTTCT polymers because citrate ions act as chelator for metal cations and thus 
poison the catalyst.  In contrast to the NO-releasing polymers, NO-generating polymers 
based on the Cu-DTTCT catalyst cannot produce NO spontaneously.  Rather, they 
require the presence of RSNO species in the aqueous phase to serve as the substrate, and 
therefore the level of NO produced depends not only on the amount of catalyst in the 
polymer phase but also on the concentration of RSNO substrate in the solution phase.  
RSNO compounds are labile and can be decomposed by a number of stimuli [41].  As a 
result, a steady level of NO-generation at the interface requires a relatively constant level 
of RSNO species being present, such as the scenario in vivo.  However, the requirement 
of stable RSNO level presents a significant challenge to the current design of the in vitro 
platelet adhesion experiment.  This is because the RSNOs will decompose during the 
incubation period as NO is being generated at the polymer/plasma interface.   
Due to its chemical instability, little endogenous RSNO can be preserved in the 
final PRP as determined by NOA.  Therefore, GSNO was added to some of the wells to 
compensate for the possible loss of endogenous RSNO during PRP preparation.  The 
wells without added GSNO serve as controls.  The NO- generation profile of polymers 
with different wt% of Cu-DTTCT is illustrated in Figure 2.4.    
However, it is important to realize that the NO-generation kinetics depicted in 
Figure 2.4 might be different from the actual rate of NO-generation in the microtiter plate 
wells.  In the measurement of NO-generation, a polymer film of 1.5 cm2 was placed in 2 
mL of PBS containing 5 μM GSNO (i.e., the surface/volume ratio is 0.75 cm-1).  When 
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Figure 2.4.  NO generation from Cu-DTTCT doped PVC polymers in the presence of 5 
μM GSNO, 30 μM GSH and 10 μM EDTA in 2 mL PBS.  
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the polymer coating (surface/volume ratio of 8.34 cm-1).  The depletion of RSNO might 
occur much faster in the microwells, as a much larger NO-generating surface was 
exposed to a given volume of aqueous RSNO solution.  Despite the higher surface-to-
volume ratio, the NO flux does not increase in the case of microwells.  This is because 
the flux depends only on the concentration of RSNO in solution and that of catalyst in the 
polymer phase, and will be normalized on the basis of surface area.   
To achieve the sustained NO-generation above 1×10-10 mol cm-2 min-1 for at least 
30 min, 2% Cu-DTTCT in PVC/NPOE was finally chosen as the NO-generating polymer 
film to coat the microtiter plate wells.  A control polymer coating was prepared with the 
same wt% of DTTCT ligand in PVC/NPOE.  The LDH assay result of platelet adhesion 
on NO-generating and control polymers, either in the presence or absence of added 
GSNO, is summarized in Figure 2.5.  It is obvious that additional GSNO can inhibit 
platelet adhesion, even in the case of control polymer.  Unfortunately, the NO-generating 
polymer does not further inhibit platelet adhesion.   
One possible reason for the inability of NO-generating polymers to inhibit platelet 
adhesion is the rapid decomposition of RSNO in the NO-generating microwells, as 
discussed above.  The NOA experiment using a much smaller NO-generating polymer 
piece per unit volume showed that NO-generation could last ~ 30 min, which is the 
typical time window for the platelet adhesion experiment.  It can be speculated that the 
duration of NO-generation will be much shorter in the microwells where the 
surface/volume ratio is more than 10 times larger.  However, due to the practical 
limitation in the NOA cell design, it is difficult to simulate the situation that exists in the 














































































is not an option, as 5 μM is by far the upper limit of physiological RSNO levels.  
Lowering the concentration of Cu-DTTCT catalyst in the polymer film is not a practical 
choice either, because it is desirable to maintain the NO flux above 1 ×10-10 mol cm-2 
min-1.  Lower catalyst amount is accompanied by lowered NO flux, as discussed earlier. 
Another variable is the photo-instability of GSNO.  Results indicate that GSNO at 
μM concentrations can be easily decomposed by light.  Exposure to light cannot be 
completely eliminated in the handling of plasma.  Therefore, it is likely that the added 
GSNO decomposes and provides a bolus of NO at the beginning of PRP incubation.  This 
may explain why NO-generating polymer cannot further inhibit platelet adhesion, since 
the added GSNO might have already been depleted by light.  This also explains why the 
control polymer, which cannot decompose RSNO, results in decreased platelet adhesion 
as well. 
The last question is the choice of RSNO species.  Besides the role of NO carrier, 
RSNO may also act directly as a platelet inhibitor [42] and the ability to inhibit platelets 
is a function of the RSNO structure.  It has been reported that GSNO is a more potent 
platelet inhibitor than some other RSNOs such as S-nitroso-N-acetyl-penicillamine 
(SNAP) [43].   Further investigation in this direction may require a search for alternative 
RSNOs that are more photo-stable and less anti-platelet in nature. 
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2.4.  Summary 
 
NO-Releasing Polymers: The thromboresistance of a healthy endothelium involves a 
complex, synergistic mechanism in which NO plays a very important role.  In this 
chapter, an in vitro platelet adhesion assay via platelet LDH release is presented to study 
the hemocompatibility of polymer films that are capable of either continuously releasing 
small fluxes of NO or catalytically generating NO from endogenous substrates, to mimic 
the function of the human endothelium.  Using this assay, it was found that continuous 
NO release from 1:1 PVC/DOS polymer film matrix at close to physiological fluxes (0.93 
- 7.05 ×10-10 mol cm-2 min-1) helps to reduce platelet adhesion from 14.0 (±2.1) ×105 cells 
cm-2 to 2.96 (±0.18) ×105 cells cm-2 on such polymer surfaces.  SEM micrographs 
support the findings of the LDH assay by showing that the platelets were fewer in 
number and less activated on the NO-releasing surfaces.  The precision of this assay is 
affected slightly by the adsorption of LDH on polymer surfaces.  Due to electrostatic 
interactions between the positively-charged polymer surface and the negatively-charged 
LDH, the actual adhered platelets on polymers with the highest NO flux could be ~ 7% 
more than that measured in this assay.  However, this false-negative is more significant 
(~ 10%) with control polymers which have the highest positive charge.  The basal LDH 
level present in plasma is likely to contribute to a common baseline for all polymers 
tested, which is difficult to precisely determine.  Nevertheless, taking such background 
levels into consideration only strengthens our finding that the LDH assay scheme can be 
employed to study, in vitro, the effect of NO release on platelet adhesion.   
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 It should be noted that the fluxes determined to reduce platelet adhesion for the in 
vitro studies described above may be different than the fluxes required to obtain a similar 
decrease in platelet adhesion when polymer surfaces are in contact with flowing whole 
blood.  This is because the surface concentrations of NO gas will vary depending on the 
composition of the flowing blood, including scavenging reactions with hemoglobin in red 
blood cells, thiol groups and normal oxidation of NO by blood oxygen.  In addition, 
platelet adhesion will also be influenced by the hemodynamics [44].  Clearly, the 
methodology reported here using microtiter plate wells coated with polymer that releases 
NO only provides a preliminary assessment as to the potential capability of such coatings 
to prevent thrombosis when used in vivo.  Ultimately, the LDH assay methodology 
described herein can also be used to assess platelet adhesion on NO-releasing materials 
that are tested intravascularly.  Such studies are currently in progress in this laboratory. 
 
NO-Generating Polymers:  The catalytic NO generation requires the concerted action 
between the RSNO species in aqueous phase and the catalyst in the polymer phase.  
Therefore, it is much more complicated to simulate in an in vitro test setting.  The 
experiment described in this chapter is the first attempt to study the biocompatibility of 
NO-generating polymers in vitro.  However, a number of serious challenges were 
encountered as discussed in Section 2.3.5.  As is the case for any biomaterial, the most 
desirable biocompatibility evaluation of NO-generating polymers would be via in vivo 
study.  An example of this is the focus of Chapter 3. 
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MORE BIOCOMPATIBLE INTRAVASCULAR OXYGEN SENSORS  
VIA CATALYTIC DECOMPOSITION OF S-NITROSOTHIOLS  





As introduced in Chapter 1, monitoring the cardiopulmonary function of critically 
ill patients mandates the continuous measurements of blood gases and electrolytes.  The 
development of implantable sensors (electrochemical and/or optical) capable of reliably 
measuring important physiological species, such as PO2 , PCO2, pH, electrolytes, glucose 
and lactate in vivo, has remained a great challenge for several decades [1, 2].  A variety of 
prototype catheter-style commercial devices have been developed for intravascular blood 
gas sensing purposes [3, 4].  However, these devices have not found widespread use in 
the clinical arena, primarily due to the erratic results obtained when used for continuous 
in vivo measurements.  Such errant results arise from the biological responses of living 
systems to foreign devices implanted in the blood stream. Proteins, such as collagen, 
fibrinogen and von Willebrand factor, adsorb onto the polymer surfaces of the implanted 
sensors within seconds [5, 6].  The adsorbed protein layer mediates the adhesion and 
activation of metabolically active cells, e.g., platelets, that later arrive [7, 8].  Platelets 
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play a key role in blood coagulation since activated platelets keep recruiting circulating 
cells to the polymer surfaces, which ultimately leads to the formation of blood clots [9].  
The presence of active cells on the surface of such devices causes  localized changes in 
pH, PO2 and PCO2 values due to cellular respiration compared to the bulk blood [1], 
yielding significant errors when results are compared to values obtained from in vitro 
measurements on discrete samples of blood.  
Nitric oxide has been widely recognized as a potent vasodilator and inhibitor of 
platelet adhesion and activation [10-13].  It is produced from L-arginine by a class of 
enzymes known as nitric oxide synthases (NOS).  The perfect thromboresistance of the 
human endothelium has been attributed in part to the low but continuous production of 
NO in this layer [14, 15].  Endothelial cells that line the inner walls of healthy blood 
vessels produce NO with an estimated surface flux level of 0.5-4.0 ×10-10 mol cm-2 min-1 
[16].  Therefore, one approach to potentially resolve the hemocompatibility problem is to 
release or generate NO locally at the blood/sensor interface at or above the flux of normal 
endothelial cells in order to inhibit platelet adhesion and activation, and thus prevent 
gross thrombus formation.  Biomedical devices (i.e., intravascular sensors, vascular grafts, 
extracorporeal circuits, etc.) coated with polymers containing diazeniumdiolate-type NO 
donors have already been shown to exhibit improved biocompatibility via various in vivo 
evaluations (in animal models) [17-19].  However, due to the limited reservoir of the NO 
donors in the polymer coatings, the NO-release approach is only suitable for biomedical 
devices that require short-term blood contact times, such as hemodialysis and 
extracorporeal circulation, but not for long-term (i.e., weeks or months) implantation.  To 
maintain NO production for extended periods of time it may be possible to take 
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advantage of endogenous species such as nitrosothiols (RSNOs) that are constantly 
produced in the body (from NO generated by NOS) to generate NO in situ at the 
polymer/blood interface. 
Nitric oxide has very short lifetime in blood [20] due to its reactivity with various 
blood components [21].  In contrast, more abundant (i.e., micromolar concentrations) and 
stable forms of NO in blood are  S-nitroso adducts with thiol groups (RSNOs) [22], such 
as S-nitrosoalbumin (AlbSNO), S-nitrosocysteine (CysNO) and S-nitrosoglutathione 
(GSNO) [22-24].  One well-known mechanism of RSNO decomposition to yield NO is 
catalyzed by Cu+ [25], in which Cu+ is produced from the reduction of Cu2+ by thiolates 
or other reducing equivalents that exist in the physiological environment (e.g., ascorbate).  
It has already been demonstrated that polymer films doped with lipophilic cyclen-type 
Cu(II) complexes [26] and Cu(II)-cylen complex covalently linked to poly(2-
hydroxyethyl methacrylate) hydrogels [27] are capable of generating significant NO 
fluxes (>1×10-10 mol cm-2 min-1) in the presence of physiologically relevant 
concentrations of GSNO and appropriate reducing agents.  However, our preliminary 
studies indicate that such polymer films based on these Cu(II)-cylen complexes are not 
ideally suited for long-term NO-generation in vivo due to the loss of NO-generating 
functionality after extended storage in plasma.  In this chapter, the use of polymer films 
doped with small metallic copper particles as the catalytic coatings on the surface of 
intravascular electrochemical oxygen sensing catheters is examined.  Such coatings can 
generate NO in situ at the sensor/blood interface via a slow corrosion of the copper 
particles to produce copper ions.  When placed in porcine arteries, the oxygen sensing 
catheters with NO-generating capability are shown to exhibit improved blood 
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compatibility and more accurate PO2 measurements when compared to corresponding 
control oxygen sensing catheters implanted within the same animals.   
 
3.2. Materials and Methods 
 
3.2.1. Materials  
Sodium chloride, potassium chloride, sodium nitrite, reduced L-glutathione (GSH), 
sulfuric acid (95-98%), bicinchoninic acid (disodium salt), dibutyltin dilaurate (95%), 
Triton X-100, bovine serum albumin and 3-μm copper powder were purchased from 
Sigma-Aldrich (St. Louis, MO).  Copper nanoparticles (80 nm size) were from Inframat 
Advanced Materials (Farmington, CT).  Ethylenediaminetetraacetic acid (EDTA) was 
obtained from Mallinckrodt (Paris, KY).  Methocel 90 HG and 3-
aminopropyltrimethoxy-silane were from Fluka (Milwaukee, WI).  The silicone rubber 
tubing (0.51 mm i.d. × 0.94 mm o.d.) used to construct catheters was obtained from Helix 
Medial, Inc. (Carpinteria, CA), and Silastic medical grade tubing (0.94 mm i.d. × 1.29 
mm o.d.) was received as a gift from Medtronic (Minneapolis, MN).  Silicone rubber 
(RTV-3140) was the product of Dow Corning (Midland, MI).  Tecophilic SP-60D-60 and 
Tecoflex SG-80A polyurethanes were from Noveon (Cleveland, OH).  A quick-setting 
two-part epoxy was the product of Super Glue Corp. (Rancho Cucamonga, CA).  The 
PTFE-coated Pt/Ir and Ag wires employed to fabricate the oxygen sensing catheters were 
products of MedwireCorp. (Mt. Vernon, NY).  Ultra 4-way stopcocks and Angiocath 
catheter guides (16g × 1.16 in) used for catheter implantation in the arteries of pigs were 
from Medex (Hillard, OH) and Becton Dickinson (Sandy, UT), respectively. 
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3.2.2. Fabrication of NO-Generating Oxygen Sensors 
The Clark-type amperometric oxygen sensing catheters employed in this work 
were fabricated as previously reported [17, 19].  However, instead of applying an NO-
release polymer coating on the surface of the silicone rubber catheter, a thin layer of a 
polymer doped with Cu0 catalyst (in the form of either micron- or nano-sized Cu0 
particles) was coated on the surface of the silicone rubber tubing (see Figure 3.1).  Briefly, 
the sensor sleeves were made by cutting the thinner silicone rubber tubing (from Helix 
Medical) into 25 mm pieces and filling ~ 2 mm length on one end with RTV-3140.  The 
sensor sleeves were cured under ambient conditions for 24 h.  Two different sizes of 
copper particles (3 μm and 80 nm) were evaluated for in vivo biocompatibility, together 
with their respective controls (polymer coating without Cu0 particles).  In the case of 3-
μm Cu0 particle coatings, 3% (w/v) of Cu0 particles were suspended in a THF solution of 
5% (w/v) RTV-3140 and 2.5% (w/v) SP-60D-60 hydrophilic polyurethane (HPPU).  This 
mixture was sonicated for 30 min before the catheter sleeves were dip-coated once in this 
suspension.  Thirty minutes later, one top-coat of 1% RTV-3140 and 0.5% HPPU (w/v) 
was applied to the sensor sleeves by dip-coating.  The coatings were first cured overnight 
at ambient moisture, and then further dried under vacuum for 24 h.  Coatings on control 
sensors were prepared in the same manner except that no copper particles were added to 
the polymer solution used for the underlying coating.   
To apply the polymer coating doped with the copper nanoparticles to the sensors, 
an adhesion-promoting layer was added between the silicone rubber sensor sleeve and the 
Tecoflex SG-80A polyurethane layer which contained the copper nanoparticles.  This 
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adhesion layer was made from 10% RTV-3140, 1% 3-aminopropyltrimethoxy-silane and 
0.1% dibutyltin dilaurate catalyst (all w/v) in THF.  This adhesion layer was cured under 
ambient moisture for 24 h before the catalyst layer was dip-coated on the sensor.  The 
catalytic layer was prepared using a THF solution with 3 w/v% of Tecoflex SG-80A and 
1 w/v% Cu0 nanoparticle catalyst and sonicated for 20 min.  The sensor sleeves with the 
adhesion promoter layer were dip-coated once in this polymer mixture and dried under 
ambient conditions overnight and then dried again under vacuum for 24 h.  Control 
sensor sleeves were coated in the same manner with the only difference being the absence 
of copper particles in the outer polymer layer.  No additional topcoat was applied to 
prepare the sensors with the nanoparticle-based coating.   
To construct the functional electrochemical oxygen-sensing catheter, the sensor 
sleeves were filled with 0.15 M KCl and 1.5 wt% Methocel internal electrolyte solution 
(see Figure 3.1).  The entire sensor sleeve was sealed and glued to the sensor body by 
epoxy.  The Teflon coated Pt/Ir working electrode was polarized at -0.7 V vs. the 
Ag/AgCl reference electrode.  Current output was recorded via a DATAQ Instruments 
DA-700 USB data acquisition card (Akron, OH) by WinDAQ/Lite software.  The 
sensor’s response to oxygen was evaluated via bench experiments by using different 
tonometered solutions of oxygen (0, 5, 10, 21 and 30% of O2, balanced with N2).  Sensors 
were placed in each solution for 10 min and the output current was recorded by the 
aforementioned protocol.  
   
3.2.3. In Vitro Nitric Oxide Generation 
































































Figure 3.1.  Schematic of intravascular oxygen sensor design and the NO generation 
mechanism 
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vivo studies using a chemiluminescence NO analyzer.  Nitrosoglutathione (GSNO) was 
prepared by the reaction of equal-molar glutathione (GSH) and NaNO2 in 0.06 M H2SO4.  
To an amber glass reaction cell containing 2 mL PBS (138 mM NaCl, 2.7 mM KCl and 
10 mM sodium phosphate, pH 7.4) was added 1 μM GSNO, 30 μM GSH and 5 μM 
EDTA (to chelate metal ion contaminates that might otherwise decompose GSNO).  The 
solution was bathed at 37 ºC and continuously bubbled withN2.  Any NO produced in the 
test solution was purged from the buffer, carried by the N2 gas into the 
chemiluminescence reaction chamber and monitored in real-time.  The baseline NO level 
was recorded for ~ 5 min before the Cu0-containing sensor sleeves were placed in the 
substrate solution. 
 
3.2.4. In Vitro Copper Corrosion 
The copper-containing sensor sleeves were bathed in 5 mL PBS (pH 7.4) for 1 d 
at 37 ºC under constant shaking.  The bathing solution was then tested for copper content 
using a bicinchoninic acid (BCA) assay as previously reported [28].  The calibration 
standards were prepared via serial dilution from a stock 1000 ppm Cu(NO3)2 (Fisher) 
solution into PBS. The absorbance at 357 nm was used for quantification.   
 
3.2.5. In Vivo Biocompatibility Evaluation  
Assessment of the in vivo biocompatibility and analytical performance of the NO-
generating oxygen sensing catheters was performed by implanting sensors in nine female 
juvenile swine, weighing 25 - 30 kg.  Six of the nine animals were used for the evaluation 
of the 3-μm Cu0 particle based coating and the remaining three animals were used to 
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assess the sensors with polymer coatings containing the Cu0 nanoparticles.  Mechanical 
gas anesthesia was maintained during the experiment with a mix of 1-3% liquid for 
inhalation isofluorane (Hospira, Inc., Lake Forest, IL) and 21% oxygen.  The depth of 
anesthesia was monitored following the University of Michigan’s University Committee 
on Use and Care of Animals protocol that was pre- approved for these experiments. 
Cut-downs of the animals were made on both groins as well as the bilateral sides 
of the neck for isolation of the femoral and carotid arteries, respectively.  An arterial 14-
gauge catheter was advanced into the right thyrocervical trunk to monitor systemic 
hemodynamics (blood pressure and heart rate) and to acquire blood samples for activated 
coagulation time (ACT) and in vitro arterial blood gas (ABG) values using a Radiometer 
Medical ABL-505 standard blood gas analyzer (Copenhagen, Denmark).  The right 
internal jugular vein was exposed and dissected from surrounding tissues and a 9 Fr 
Arrow® catheter was advanced to monitor central venous pressure (CVP), and to further 
administer i.v. fluids (lactated ringers) and medications.  The arterial and CVP lines were 
attached to fluid pressure transducers (Abbott Critical Care Systems. North Chicago, IL) 
and monitored continuously on a Series 7000 Pressure Monitor (Marquette Electronics, 
Milwaukee, WI).  The bladder of each animal was surgically drained by placing a Foley 
catheter directly into the bladder.  
For each swine, four sensors were implanted: two NO-generating sensors and two 
control sensors.  One NO-generating sensor and one control sensor were placed in the 
carotid arteries, while the second pair was placed in the femoral arteries via 16-gauge 
Angiocath 1.16 inch cannulae.  The cannula tips were trimmed off by ~ 1 cm to make an 
angle that allows for the ease of intravascular implantation.  Sensors were slid into the 
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cannulae and fixed to the 4-way stopcock by epoxy. Approximately a 1 cm length of the 
sensing catheter extended past the end of the cannula and was exposed to flowing blood 
in the animal.  The artery distal to the cannula insertion was not ligated. Slow saline drips 
(0.1-0.2 mL/min) containing 1 U/mL of heparin were supplied to each sensor site via 
pressure bags to prevent back-flow of blood into the cannulae. Sensors were implanted 
such that the sensor tip was exposed to oncoming blood flow and the small amount of 
heparin present in the saline drips was washed distally from the sensor, never flowing 
over the sensor surface.  
No systemic anticoagulation agent was administered during each animal study.  
Activated coagulation times (ACT) were measured before sensor implantation and was 
checked every 4 h during the experiment to ensure that the slow heparin infusion does not 
lead to any significant systemic anticoagulation.  One hour after implantation, sensors 
were calibrated in situ via a one point calibration (assuming zero current for zero oxygen 
level and that the observed current corresponds to the blood oxygen PO2 level measured 
in vitro by the ABL-505 blood gas monitor at the point of calibration).  Continuous 
amperometric sensor output was recorded, and discrete blood samples were drawn 
periodically and analyzed by the ABL-505 to evaluate the accuracy of the implanted 
sensors’ performance. During the first 2 h, blood samples were drawn every 15 min, and 
during hours 3-4, samples were drawn every 30 min. During the remainder of the 
experiment, samples were drawn every hour for comparison purposes. In total, 24 oxygen 
sensing catheters were evaluated (12 NO-generating sensors and 12 controls) in the 3-μm 
particle group and a total of 12 (6 NO-generating and 6 controls) were studied in the 
nanoparticle group.  
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 Upon termination of every animal preparation, the femoral and carotid arteries 
were excised distal to the implanted sensor. The animal was then euthanized with a bolus 
injection of Fatal-Plus (Vortech Pharmaceutical, Dearborn, MI).  To prevent scraping off 
of the surface bio-layer, the sensors were carefully dissected from the arteries without 
pulling them out of the vessels or through the cannula, and rinsed in PBS to remove 
loosely adsorbed blood elements.  
 
3.2.6. Surface Clot Evaluation   
Digital images of the oxygen sensing catheters were taken immediately after the 
removal of sensors from the blood vessels.  A lactate dehydrogenase (LDH) assay has 
been reported previously (see Chapter 2) as a useful approach for quantifying platelet 
adhesion to surfaces [29].  In this chapter, this LDH assay was used to assess the degree 
of gross thrombus and cell adhesion on the sensor surfaces after the in vivo experiments.  
The portion of catheter tips that had been exposed to the blood stream was cut off and 
stored in 1.5 mL lysis buffer solution (PBS buffer with 1 wt% Triton X-100 and 0.75 
wt% bovine serum albumin) for 1 h to lyse any cells that were adhered on the catheter 
surfaces.  The copper-loaded catheter tips were then saved and later tested for the NO 
generation in vitro to assess whether exposure to flowing blood significantly changes the 
ability to catalyze the RSNO decomposition.  The lysate solution was then further diluted 
1:5 with the lysing buffer.  One hundred μL of the final lysate was mixed, in triplicate 
samples, with 100 μL of reagent from an LDH assay kit (Roche Applied Sciences, 
Indianapolis, IN) into wells of a 96-well polystyrene microplate (Fisher) and the 
absorbance at 490 nm was monitored by a Labsystems Multiskan RC microplate reader 
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(Fisher).  The linear portion of absorbance vs. time curve was used for quantitating LDH 
activity.  
 
3.3. Results and Discussion 
 
3.3.1. NO-Generating Polymer Coatings   
In preliminary experiments, a variety of polymer matrices containing 3-µm Cu0 
particles were tested, among which the 2:1 blend of RTV-3140 silicone rubber and 
Tecophilic SP-60D-60 HPPU yielded the optimal balance of adhesiveness to the SR 
tubing of the catheter and adequate hydrophilicity to allow diffusion of RSNO species 
into the polymeric layer containing the Cu0 particles.  The optimal particle:polymer ratio 
(40 w/w% for 3-μm and 33 w/w% for 80-nm particles) was determined by the peak 
fluxes of NO generation from GSNO for each formulation.  Another goal was to use the 
least possible amount of copper so as to minimize any potential toxic effects [30] that 
may be caused by continuous copper corrosion.  Previous in vivo experiments [17, 19] 
that employed NO-releasing polymer films required thick polymer coatings (~100 μm) in 
order to achieve the desired  flux and duration of NO release.  Since the NO-generation 
strategy suggested here only requires a very thin layer of Cu0 catalyst to be immobilized 
at the sensor surface, the thickness of the sensor coating with 3-µm particles could be 
reduced to as little as ~ 7 μm, while coatings can be even thinner for films containing the 
Cu0 nanoparticles.   At the same time, using the 3-μm Cu0 particles produces slightly 
rougher sensor surfaces than the controls (based on scanning electron micrographs (SEM), 
not shown here). This may put the NO-generating sensors at a disadvantage since rougher 
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surfaces are prone to induce more thrombus formation [31]. However, it was found that 
much smoother surfaces can be readily achieved using the polymer films containing the 
Cu0 nanoparticles as the catalytic layer, with negligible change of surface roughness as 
determined by SEM.  The utilization of an adhesion promoter layer allows for the use of 
polyurethanes as the coating material to load the copper nanoparticles on the silicone 
rubber surfaces of the catheters.  Tecoflex SG-80A was found to offer the best 
combination of NO flux and adhesive properties in this case. 
In preliminary in vitro experiments to assess NO generation capability of the 
different coatings, the GSNO and GSH concentrations were set at 1 μM and 30 μM, 
respectively, which is close to their physiological levels [23].  As shown in Figure 3.2, 
the NO-generating polymer coatings on sensor sleeves, either made from 3-μm (Figure 
3.2-1) or 80-nm Cu0 particles (Fig. 3.2-2), were capable of generating physiologically 
relevant ( >1×10-10 mol cm-2 min-1) levels of NO both before and after implantation 
within a porcine artery for 20 h.  The levels of generated NO detected by 
chemiluminescence decrease over time as the GSNO substrate in the test solution is 
consumed.  The sensor sleeves tested were different in length before (25 mm) and after 
(10 mm) the in vivo study, as only the exposed portion was taken after the implantation.  
Thus, the NO flux data were normalized to reflect this change in surface area.  
Interestingly, the sensors coated with polymer containing the 3-μm Cu0 particles actually 
generated higher fluxes after the in vivo experiment.  This might be due to the hydrophilic 
moiety in the polymer becoming more completely hydrated allowing for faster GSNO 
diffusion into the film.  Although there is no method currently available to directly 
measure the NO fluxes at the sensor surfaces in vivo, it is anticipated that the oxygen 
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Figure 3.2. In vitro generation of NO from 1 μM GSNO, 30 μM GSH and 5 μM EDTA 
in 2 mL PBS at 37ºC by the catalysis of (1) 3 μm and (2) 80 nm Cu0 particle 
coated sensor sleeves before and after animal studies. 
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sensors coated with the films containing the Cu0 particles are, in fact, able to continuously 
generate NO in vivo from endogenous RSNO substrates.   
Our previous results with NO-releasing polymers showed that NO released from 
the sensor surface does not interfere with its oxygen measurements during the time frame 
of the in vivo experiments [17].  In this study, the possible effects of adding the copper 
particles to the outer layer of the sensor on the amperometric oxygen sensitivity and 
response times of the devices were also examined.  Figure 3.3 illustrates the typical 
current responses to different levels of PO2 displayed by the NO-generating sensors based 
on the 3-μm and nano-Cu0 particles embedded in the outer polymer coatings.  As shown, 
the introduction of the Cu0 catalysts does not significantly impact the electrochemical 
oxygen response of the sensors, with responses linear to at least 227 mmHg (30% O2 
balanced by N2) and no dramatic change in response time (compared to control sensors 
without the coatings).  As shown in Figure 3.3, the output currents of given sensors do 
vary as the result of different working electrode areas exposed in the fabrication step.  
This is the reason why in vivo calibration needs to be performed at the beginning of each 
experiment. 
 
3.3.2. In Vitro Copper Corrosion 
Since it is known that the catalytic species required to decompose RSNO species 
to NO is either Cu(I) or Cu(II) ions, the NO generation process observed must be due to a 
slow corrosion of the metallic copper particles in the polymeric matrix. Further, copper is 
an essential trace element in biological systems.  The average intake of copper by human 















Figure 3.3.  Amperometric responses of NO-generating oxygen sensors prepared with 3 
μm and 80 nm Cu0 particle coatings to 0, 5, 10, 21 and 30% oxygen balanced 




healthy functioning of organisms, excess copper build-up in the body could cause 
Wilson’s disease which may lead to impaired liver function [30].  Given that NO-
generation of the outer polymeric layers of the oxygen sensing catheters relies on the 
corrosion of metallic copper particles to provide reactive surface ions, it is critical to 
establish that copper corrosion is well below the level required for safe use under 
physiological conditions.  Copper analysis via the colorimetric BCA assay has excellent 
sensitivity and selectivity, and the results have been reported to correlate very well with a 
conventional atomic absorption method [28].   Using this assay, the levels of copper ions 
present in PBS solutions in which a Cu0 particle based coatings were soaked in for at least 
24 h were measured.   The corrosion rate for copper was determined to be 4.84 ± 0.37 
μg/d (N = 4) per catheter sleeve for coatings that contain the 3-μm Cu0 particles and 0.78 
± 0.17 μg/d (N = 3) for the Cu0 nanoparticle-based coating.  In both cases, this is less 
than 1% of the recommended daily intake for human adults [32].  Therefore, with only 4 
relatively small sensors implanted in each animal, it is unlikely that copper leaching from 
the surface of the sensors will have any toxic effects.  Moreover, the sensors were 
implanted in a dynamic flow environment so that there would not be any locally 
accumulated copper levels to be concerned about.  In fact, no unusual inflammation was 
observed at any of the sensor implant sites that were used to carry out the animal 
experiments reported in this study.   
 
3.3.3. Blood-Compatibility and Surface Thrombus Evaluation 
3.3.3.1. 3-μm Cu0 particle coated sensors  
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Without administration of a systemic anticoagulation agent, 12 pairs of control 
and NO-generating sensors were implanted in porcine carotid and femoral arteries for at 
least 20 h.  The animals’ ACTs remained within the normal range of 75-120 s throughout, 
suggesting no systemic effects of the heparin drips at each sensor site.  Any gross thrombi 
on the surfaces of the implanted sensors were determined by observing formation of 
mature blood clot with a dark color and fibrin networks after the sensors were excised 
from the arteries.  For all the oxygen sensors implanted, 9 of 12 control sensors showed 
visible thrombus formation after being explanted and rinsed in PBS; in contrast, only 3 of 
12 NO generating sensors had visible clots on them. In all cases where one or two NO-
generating sensors developed observable blood clots, both control sensors in the same 
animal had significant clots over them as well.  This might imply that lower than normal 
RSNO levels existed in these test animals.  In such cases the NO-generating functionality 
of the Cu0 particle coatings would not provide adequate surface levels of NO to improve 
thromboresistancy.   
Two representative pairs of sensors in the 3-μm Cu0 particle group after 
explantation are shown in Figure 3.4-1 and Figure 3.4-2, each pair from the same animal.  
In each panel (A) represents NO-generating sensors and (B) represents the control 
sensors.  To the right of the dashed lines is the portion of the sensors that have been 
exposed to blood flow.  In general, NO-generating sensors are darker in color than the 
controls due to the copper particles in the outer polymeric coating.  Both NO- generating 
sensors (i.e., A1 and A2) appear clean. However, a mature blood clot has developed over 
control sensor B1.  Control sensor B2 appears to be free of clot.  Only 3 of 12 control 
























Figure 3.4.  Images of four representative pairs of NO-generating (Panel A) and control 
(Panel B) sensors after in vivo studies.  The portion to the right of the dotted 
lines had been exposed to blood.  Sensors A1, B1, A2 and B2 are from the 
3-μm particle group while Sensors A3, B3, A4 and B4 are from nanoparticle 
group. 
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SEM is normally used for the surface analysis of blood-contacting materials [33].  
It is ideal in providing detailed image at a very small region of the surface but fails to 
give quantitative information on a macroscopic scale.  In this study, an LDH assay was 
used to better quantify platelet and other cell adhesion to surfaces of the implanted 
oxygen sensing catheters.  LDH is a very important metabolic enzyme commonly found 
in blood cells and an LDH assay has already been used in determining the degree of 
platelet adhesion to surfaces  in vitro [29, 34, 35].  The LDH content of a given cell is 
normally proportional to its size [29].  Table 3.1 lists the corresponding LDH assay 
results of the two specific pairs of sensors examined above.  Not surprisingly, sensor B1 
exhibited substantial LDH activity in the resulting lysate solution (37.4 mU) whereas 
sensor A1 showed significantly less LDH activity. Overall, a summary of LDH assay 
data for all 3-μm Cu0 particle coated sensors (N=12) and their corresponding controls is 
provided in Table 3.1.   As can be seen, the average amount of LDH activity on control 
sensors is nearly 10 times the levels found on the sensors fabricated with the polymer 
coating containing the 3-µm copper particles.  These two data sets are statistically 
different at the 95% confidence interval (p = 0.022 with 22 degrees of freedom). 
 
3.3.3.2. Cu0 Nanoparticle Coated Sensors 
Coatings with Cu0 nanoparticles yielded similar results as those with 3-μm Cu0 
particles.  Overall, three out of six control sensors developed mature blood clots on the 
surface while only one NO-generating sensor had surface clot.  Figures 3.4-3 and 3.4-4 
also show two typical pairs of nanoparticle-coated sensors.  Sensors A3 and A4, the two 
NO-generating devices, both turned out to be relatively clean after 19 h of implantation.   
78 










Sensor Group NO-generating (A) Control (B) 
A1 & B1 0.14 37.4 
A2 & B2 1.67 0.11 
3-μm particle (N=12) 2.97 ± 2.05 24.1 ± 20.9 
A3 & B3 5.18 38.8 
A4 & B4 5.32 4.07 








Table 3.1.  LDH assay of surface clots for the 4 pairs of sensors examined in Figure 3.4, 
and the statistical results of LDH levels in the two groups. 
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Control sensor B4 was also free of blood clot.  However, a mature clot that developed 
around control sensor B3 had completely engulfed the sensing tip.  The LDH assay 
results for these two pairs of sensors, as well as the statistical analysis of the entire Cu0 
nanoparticle test group (N=6), are summarized in Table 3.1.  Again, on average, the 
sensors coated with the polymer film containing the Cu0 nanoparticles tend to have much 
lower LDH activity originating from their surfaces, suggesting that much less cell 
adhesion occurs for this group.  The difference in LDH activities between NO-generating 
and control sensors in this category is also statistically significant (p = 0.013).   The LDH 
assay results are not affected by the small amount of corroded copper that is present in 
the lysate solution.  A control experiment with free LDH in the presence and absence of 1 
μg/mL Cu2+ ions (much higher than the possible amount of leached copper during the 1 h 
incubation period, see 3.2) showed the same LDH enzyme activities.   
 
3.3.4. In Vivo O2 Sensor Performance  
3.3.4.1. 3-μm Cu0 Particle Coated Sensors 
The corresponding PO2 levels determined by the two pairs of sensors from 
Figures 3.4-1 and 3.4-2, as well as the ‘true values’ obtained from in vitro blood gas 
analyzer measurements over 20 h of implantation, are shown in Figures 3.5-1 and 3.5-2.  
Implanted sensors are able to track closely with the PO2 values measured by benchtop 
blood gas analyzer when their surfaces are not covered by blood clots, as were the cases 
for both NO-generating sensors in Figures 3.5-1 and 3.5-2, and the control sensor in 
Figure 3.5-2 (sensor B2).  However, when blood clots develop over the sensor surfaces, 
the metabolism of cells within the clot consumes oxygen, rendering false-negative in the 
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PO2 measured by such sensors.  The extent of surface clot dictates the deviation from true 
values.  As seen in Figure 3.5-1, sensor B1, which had a complete coverage of clot over 
the sensing tip started to show false-negative oxygen values 5 h into the experiment and 
eventually provided readings that were ~ 20% of the true PO2 values.  On the other hand, 
control sensor B2 in Figure 3.5-2, and both NO-generating sensors (A1 and A2) in 
Figures 3.5-1 and 3.5-2, which had clean surfaces, traced PO2 levels quite accurately.  
Such variations in the analytical performance of control sensors reflect the 
biocompatibility issues usually encountered with intravascular sensors, with some sensors 
completely covered by blood clot while others remain relatively clean.   
Figure 3.6-1 summarizes the in vivo analytical results for both NO-generating and 
control sensors (N = 12 each) in the 3-µm copper particle coated group.  The average 
percent deviations (from the true values derived from benchtop blood gas machine) of O2 
levels determined by each set of implanted sensors, as well as their standard deviations, 
are plotted as a function of time.  It is clear that the NO-generating sensors yield more 
accurate PO2 results overall, with the percentage deviation ranging only from -12% to + 
9% and the average values of PO2 nicely straddling the true values throughout the 
experiment.  The control sensors, however, consistently exhibited negative deviations 
greater than -20% from the 6 h point forward, with the largest average error being -42% 
at the 12 h time point.  
Such lowered responses to O2 correlated very well with the observed surface 
thrombosis on these control sensors.  The standard deviations of the control set were also 
significantly larger than those in the NO-generating set.  Table 3.2 lists the average 
percent deviation of NO-generating and control sensors at 5, 10, 15 and 20 h time points 
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as well as their 95% confidence intervals.  The difference between the measurements 
made by NO-generating sensors and those derived from benchtop blood gas machine 
(considered 100% accurate) was not statistically significant at any time point during the 
experiment.  In contrast, the control sensors showed statistically significant differences 
(at 95% confidence) at the 15 and 20 h time points when compared to in vitro blood gas 
results.  Indeed, the control sensor results were statistically different from blood gas 
values from 11 h onwards.  Moreover, the PO2 values measured by control sensors were 
statistically different from that measured via NO-generating sensor at 95% confidence 
level (t = 2.31, p = 0.031 with 22 degrees of freedom) at the final 20 h time point.  
Although the majority of NO-generating sensors remained thrombus-free after 
explantation and most control sensors were covered with blood clots, the small fraction of 
clotted NO-generating sensors and thrombus-free control sensors significantly impacted 
the PO2 measurements made within the respective category.  For the sake of clarity, such 
‘abnormal’ sensors were excluded from the 3-μm group and the PO2 outputs from the 
remaining truly thrombus-free NO-generating sensors and clotted control sensors (N=9 
each) are plotted in Figure 3.7.  It can be seen that the standard deviations of each type of 
sensors were narrowed and the average PO2 values reported by the control sensors were 
even lower.  Indeed, at each hour after the 5 h time point, the average PO2 levels reported 
by the NO-generating sensors vs. controls were statistically different at 99% confidence 
interval (t ≥ 3.67, p ≤ 0.0021 with 16 degrees of freedom). 
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Figure 3.6.  Plots of the average percent accuracy of: (1) NO-generating sensors based on 
3-μm Cu0 particles and control sensors (N = 12 each), and (2) NO-
generating sensors based on 80 nm Cu0 particles and control sensors (N = 6 
each), as compared to in vitro blood gas analyzer results, which were 













































































































































5 + 8.6 ± 15.1% -13.6 ± 20.6% 
10 - 4.4 ± 18.6% -29.3 ± 30.3% 
15 - 0.8 ± 19.5% -29.6 ± 26.4% 





Table 3.2.  Average percent deviation and the 95% confidence intervals for PO2 
measurements made by sensors in the 3 μm particle group. 
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3.3.4.2. Cu0 Nanoparticle Coated Sensors 
PO2 values recorded from the same two pairs of Cu0 nanoparticle coated sensors 
shown in Figures 3.4-3 and 3.4-4 are illustrated in Figures 3.5-3 and 3.5-4.  The results 
are quite similar to those observed with the 3-μm Cu0 particle coatings. Sensors with little 
or no blood clots (i.e., sensors A3, A4 and B4) traced well with corresponding in vitro 
blood gas measurements.  In contrast, sensor B3, a control sensor, which was completely 
covered by clot, yielded significantly lower PO2 values from the 5 h point forward and 
actually reported values of oxygen that were near zero.    
Figure 3.6-2 provides a summary of the in vivo oxygen sensing data obtained 
from the six pairs of sensors coated with the copper nanoparticle layer.  Again, NO- 
generation via the presence of the Cu0 nanoparticle catalyst provides more accurate in 
vivo measurements of PO2 throughout the 19 h implantation period.  The average percent 
deviation from in vitro blood gas readings ranged from -11% to +12%.  Control sensors 
show considerable (> 20%) false negatives after 5 h into the experiment, with average 
PO2 values deviating up to -36% at 10 h.  Like the control group of 3-μm Cu0 particles, 
greater standard deviations were also observed in the nanoparticle control sensor group.  
The average percent deviation at 5, 10, 15 h and the 95% confidence interval of 
measurements derived from each group are listed in Table 3.3.  Statistical analysis of the 
data shown in Table 3.3 for the nanoparticle coated sensors indicates that the NO-
generating sensors accurately traced PO2 levels at the 95% confidence interval level (no 
statistically significant deviations from in vitro values), but the control sensor 
measurements did not agree with the true values at the same confidence interval from the 
















NO-generating sensors Control sensors 








5 + 2.4 ± 10.9% -20.2 ± 35.6% 
10 - 6.5 ± 6.6% -36.5 ± 35.3% 




Table 3.3.  Average percent deviation and the 95% confidence intervals for PO2 





Copper particle-based polymer coatings capable of generating physiological 
levels of NO in the presence of endogenous RSNO species have been applied to the 
surface of intravascular electrochemical oxygen sensing catheters.  These sensors, when 
tested in vivo via a porcine artery model, exhibit improved blood-compatibility over the 
control sensors as evidenced by less propensity toward surface thrombus formation and 
more accurate analytical results.  Three out of 12 NO-generating sensors in the 3-μm 
particle group, and 1 out of 6 NO-generating sensors in the nanoparticle group showed 
some degree of blood clot on the surfaces.  This might be the result of low RSNO levels 
in these animals and hence NO levels generated were not sufficient to completely 
suppress thrombus formation.  It should also be noted that the surfaces of NO-generating 
sensors were not as smooth as those of the control sensors, especially  for the larger 
copper particles, which is a disadvantage in terms of preventing clot formation.  However, 
there is still a statistical difference between the two groups of sensors.  At 95% 
confidence level, the NO-generating sensors agreed very well with in vitro blood gas 
measurements with no statistically significant differences throughout the experiment. On 
the other hand, control sensors results were statistically different from in vitro blood gas 
measurements after about 10 h implantation. 
The control sensor behavior found in this work is representative of intravascular 
sensing devices developed thus far, which explains their limited use in real clinical 
applications.  The NO-generation strategy offers a potential solution to this problem and 
may find use in other blood-contacting devices as well.  Ongoing research in this group is 
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focusing on covalently linking various species to polymers that can provide the same 
NO-generation capability as the copper particles used here.  New polymers containing 
immobilized organoselenium species [36] appear most promising as new NO generating 
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FURTHER STUDIES AND BIOMEDICAL APPLICATIONS OF 






S-Nitrosothiols (RSNOs) play important roles in the storage, transport and 
metabolism of nitric oxide (NO) [1].   The physiological properties of RSNOs are similar 
to those of NO in terms of vasodilation [2, 3] and inhibition of platelet activation and 
aggregation [3, 4].  Endogenous RSNO formation may occur through the reaction 
between cysteinyl residues on peptides/proteins and the reactive intermediates of NO 
(e.g., NO+, ONOO-) [5, 6].  Such oxidative intermediates of NO can also react with low 
molecular weight thiols (cysteine, glutathione, etc.) to form corresponding S-nitrosothiols 
(see Figure 4.1).  The S-nitrosation of thiols in vivo is a reversible process. Therefore, 
transnitrosation can occur in which the nitroso- group is transferred from one S-
nitrosothiol to another thiol through the nucleophillic attack of the thiolate anion on the 
nitrogen atom of the S-nitrosothiol [7, 8].  Although the biological lifetime of RSNOs is 
substantially longer than that of the free radical NO [9], they are still relatively labile and 
are subject to thermal-,  photo- and trace metal ions (e.g., Cu+, Fe2+) induced 




























Figure 4.1. Structures of representative endogenous LMW RSNOs 
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thought to be mediated by cellular surface proteins which can decompose RSNO to yield 
NO in vivo [11-13].  Recently, it has also been discovered that organoselenium 
compounds and proteins that contain selenocysteine moieties, such as glutathione 
peroxidase (GPx), are also capable of decomposing RSNOs [14].  Not surprisingly, GPx 
has also been found to inhibit platelet activation [15].   
In addition, RSNOs have been suggested as a potential biological marker for 
endothelial function [16].  Kelm and co-workers assessed the endothelial function of 
healthy volunteers and patients with cardiovascular risk factors (e.g., hypertension, 
hypercholesterolemia, smoking, or diabetes) by flow-mediated dilation and measured the 
concentrations of total plasma nitroso-compounds (RXNO: the sum of S-nitrosothiols, N-
nitrosamines, and iron-nitrosyl species) from all human subjects [17].  It was found that 
endothelial dysfunction is associated with the depletion of nitroso-/nitrosyl- species in 
plasma, which is likely to contribute to the increased risk of major cardiovascular events 
such as heart attack, stroke and thrombosis.   
As a result of the growing interests in the physiological and pharmacological 
importance of RSNOs, numerous approaches have been devised to determine the level of 
RSNOs in biological fluids, including colorimetric [18], fluorometric [18-20], 
chemiluminescent [21, 22], and ‘biotin-switch’ assays [23].  The coupling of the above 
detection techniques with high-pressure liquid chromatography has also been employed 
by many researchers to study biological RSNO concentrations [8, 24, 25].  However, 
these techniques are not capable of direct measurements of RSNOs in biological samples.  
Rather, complex sample pre-treatments are required and the detected signals originate 
from the reactions between the decomposition products of RSNO and the added 
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reagent(s).  For example, HgCl2 cleavage of RSNOs yields nitrite in the presence of 
oxygen, which can either be quantified colorimetrically via the Griess assay or 
fluorometrically after the reaction with 2,3-diaminonaphthalene [18] or 4,5-
diaminofluorescein [20].  Reductive chemiluminescence, which detects NO instead of 
RSNO, requires the conversion of RSNO to NO by reduction (e.g., triiodide or 
Cu(I)/Cysteine) prior to analysis.  In addition, the popular triiodide chemiluminescence 
assay requires three separate measurements of the plasma samples in order to obtain 
RSNO concentration data [26].  Due to the intrinsic instability of RSNO species and the 
artifacts that may be introduced during the pre-treatment steps [27, 28], such as the 
contribution from endogenous NO/NO2-, or the decomposition of RSNO before analysis 
by reacting with trace metal ions, these methodologies yield highly variable values of 
RSNO concentrations in biological fluids.  A recent review by Giustarini et al. 
summarized the reported normal levels of RSNOs in human and animal plasma, which 
range from 20 nM to 7 μM [29].  Further, since blood must be spun down to remove red 
cells for all existing measurement techniques, even a low level of hemolysis can create 
free oxyhemglobin in the plasma that can scavenge NO liberated from the RSNO species 
prior to NO detection [30].  For these reasons, while measurement of total RSNO levels 
may be a good biomarker for endothelial function testing (as well as thrombotic risk 
assessment due to their inherent anti-platelet activity), methods must be devised to 
determine total RSNO levels in the plasma of whole blood samples freshly drawn from 
the patient without time delay or pretreatment steps. 
Electrochemical sensors have already been employed to determine NO 
concentrations in various media, including biological fluids [31-34].  Cha et al. recently 
97 
reported an amperometric RSNO sensor based on a modified amperometric NO sensor 
with immobilized organoselenium catalyst (e.g., RSePEI, 3,3’-dipropionic acid diselenide 
(SeDPA) crosslinked onto polyethylenimine backbones) behind a dialysis membrane (see 
Figure 1.3) [35].  Such an RSNO sensor offers a potentially convenient approach to 
quantify total RSNO concentrations in blood without prior separation.  Indeed, in 
principle, blood can be analyzed for RSNO content immediately at the bedside without 
any sample pretreatments.  In contrast to a previously described Cu-catalyst based RSNO 
sensor [36], the major advantage of the Se-catalyst based sensor is the nearly equal  
sensitivity towards all low molecular weight (LMW) RSNO species (e.g., S-
nitrosoglutathione (GSNO), S-nitrosocysteine (CysNO)), thus making it more appropriate 
to assess the ‘global’ concentration of LMW RSNO species in biological samples.  In this 
chapter, further characterization of this new RSNO sensor with respect to response 
towards macromolecular RSNOs (e.g., S-nitrosoalbumin, AlbSNO), and effect of 
hemoglobin levels on samples are discussed.  In addition, the first application of the 
sensor to assess RSNO levels in samples of whole rabbit and pig blood is described. 
 
4.2. Materials and Methods 
 
4.2.1 Materials 
Microporous poly(tetrafluoroethylene) (PTFE) membranes (Tetratex, pore size 
0.07 μm, thickness ~18 μm) were obtained from Donalson Co., Inc. (Minneapolis, MN).  
Dialysis membranes (Spectra/Por 7, MW cutoff = 50 kDa) were purchased from 
Spectrum Laboratories Inc. (Rancho Dominguez, CA).  Polyethylenimine (PEI, avg. Mw 
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760 kDa), cysteine, glutathione (GSH), bovine serum albumin (BSA), 1,4-
dithiothreitol  (DTT),  ethylenediamine tetraacetic acid (EDTA), glutaraldehyde (25 wt% 
solution), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), N-
hydroxylsuccinimide (NHS), sodium borohydride, and sodium nitrite were products of 
Sigma-Aldrich (St. Louis, MO) and were used as received.  3,3’-Dipropionic acid 
diselenide (SeDPA) was synthesized as described in the literature [37]. Phosphate-
buffered saline (PBS, 138 mM sodium chloride, 2.7 mM potassium chloride, 10 mM 
sodium phosphate, pH 7.4), as well as all other solutions used in this work, were prepared 
in the laboratory from Milli-Q grade deionized water (18.2 MΩ, Millipore Corp., 
Billerica, MA). 
 
4.2.2. Preparation of S-Nitrosothiols 
 Solutions of S-nitrosocysteine and S-nitrosoglutathione (5 mM of each) were 
prepared by reacting the corresponding thiols with acidified NaNO2 according to a 
previously described procedure [38].  S-Nitrosoalbumin was synthesized by first reducing 
BSA with DTT before the reaction with acidified NaNO2 [39].  The RSNO solutions 
were kept in dark and used within 4 h of preparation. 
 
4.2.3. Fabrication of Amperometric NO/RSNO Sensors 
The organoselenium-containing PEI catalyst (RSePEI) was synthesized by 
coupling PEI to activated SeDPA via the EDC/NHS chemistry, and the resulting RSePEI 
was then crosslinked onto a dialysis membrane with glutaraldehyde.  The detailed 
procedure has been described elsewhere [39].  Sensors used in this study were the 
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miniaturized version of the previously reported design [35].  Briefly, Pt/Ir wire (10Ir7T, 
0.18 mm diameter, Medwire, Mt. Vernon, NY) without PTFE coating was sealed in a 
glass capillary and further platinized to form the working electrode.  The Ag/AgCl 
reference electrode was made from Ag wire (Ag3T, Medwire, with the Teflon coating 
stripped off) immersed in 100 mM phosphate buffer (pH 4.4) containing 50 mM NaCl 
and 0.005% Methocel 90 HG (Fluka, Buchs, Switzerland) as the internal solution.  The 
gas-permeable microporous PTFE membrane was treated with 0.5 μLTeflon-AF (DuPont 
Fluoroproducts, Wilmington, DE) and mounted on the sensor body made from a 200 μL 
micropipette tip.  To prepare the catalytic membrane, 3 wt% of the RSePEI solution was 
mixed at a 1:1 ratio with 1 wt% of glutaraldehyde, and 10 μL of this mixed catalyst 
solution was applied onto a dialysis membrane of ca. 0.5 cm2 in size.  In the RSNO 
sensor, the RSePEI immobilized dialysis membrane was attached to the outside of the 
gas-permeable membrane with an O-ring, with the RSePEI hydrogel layer trapped 
between the dialysis membrane and PTFE gas-permeable membrane of the NO sensor.  
For the NO sensor, a blank dialysis membrane without the immobilized catalyst was used 
to assemble the device.  Both sensors were polarized at + 0.75 V vs. Ag/AgCl overnight 
prior to use.  All subsequent calibrations and measurements were performed at the same 
applied potential. 
 
4.2.4. NO and RSNO Sensor Calibrations 
Amperometric measurements were performed using Diamond Electro-Tech 
electrochemical analyzers (Ann Arbor, MI) interfaced with a Dataq DI-158U 
analog/digital data acquisition device (Dataq Instruments, Akron, OH).  The NO and 
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RSNO sensors were both placed in a home-made amber glass cell (25 mL capacity) 
containing 10 mL PBS with 0.5 mM EDTA.  The solution was deoxygenated with N2 and 
the temperature was maintained at 34 ºC throughout the experiment.  During the NO 
calibration, small aliquots of saturated NO solution (contains 1.9 mM NO at room 
temperature) were injected into the buffer under a N2 atmosphere and the responses from 
both sensors were simultaneously recorded by the WINDAQ software (Dataq 
Instruments).   RSNO calibration was performed under N2 bubbling by injecting GSNO 
into the same buffer with 100 μM of GSH present as the reducing agent.   
 
4.2.5. Detection of Macromolecular RSNOs 
S-Nitrosoalbumin (AlbSNO) was prepared from reduced BSA and acidified 
NaNO2 following a reported procedure [39].  The AlbSNO concentration was determined 
via a chemiluminescence Cu(I)/cysteine assay [40].  In the electrochemical measurement, 
the same dual sensor configuration as in NO/RSNO calibration was adapted.  A certain 
amount of AlbSNO was injected into 10 mL PBS buffer containing 0.5 mM EDTA and 
100 μM reducing agent (i.e., GSH or cysteine).  The amperometric responses to each 
injection of AlbSNO were recorded and later converted to LMW RSNO equivalents 
based on previous calibrations with the LMW RSNOs that correspond to the given 
reducing agent used in the experiment. 
 
4.2.6. Matrix Effects in Physiological Fluids 
4.2.6.1. RSNO Sensitivity in Diluted Plasma  
101 
Rabbit plasma was obtained by centrifuging heparinized rabbit whole blood at 
110 ×g.  Five mL of the plasma was diluted into 10 mL PBS with 1.5 μmole GSH and 7.5 
μmole EDTA (yielding final GSH concentration of 100 μM and EDTA concentration of 
0.5 mM).  GSNO calibration was performed using the same protocol described in the 
RSNO calibration section and was compared with the results obtained from buffer only. 
 
4.2.6.2. Free Hemoglobin Effect 
The red blood cell concentrate from plasma separation was lysed in a 1:4 dilution 
with 10 mM EDTA as previously reported [41] and centrifuged at 1300 ×g to remove 
membrane fragments.  The concentration of free oxyhemoglobin was determined from 
UV-Vis by the method reported by Benesh et al [42].  For GSNO calibration, 15 mg/dL 
oxyhemoglobin was added in addition to all other reagents used in the aforementioned 
GSNO calibration procedure to simulate the typical level of plasma free hemoglobin.   
 
4.2.7. Photo-Decomposition of Blood RSNO 
The dual-sensor configuration was also employed for whole blood RSNO 
measurements.  Ten mL of deoxygenated PBS containing 1.5 μmole GSH and 7.5 μmole 
EDTA was equilibrated at 34 ºC under a N2 atmosphere prior to blood injection until a 
steady baseline amperometric signal was achieved for both sensors.  Blood samples from 
pigs were collected by venipuncture in the abdomen via a butterfly needle (23G, Abbott, 
North Chicago, IL) into a 5 mL heparinized syringe (5 U/cc final heparin) wrapped in Al 
foil.  To evaluate the effect of light exposure on the stability of RSNO species in blood, 
another blood sample was drawn from the same animal with the 1 ft long butterfly tube 
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wrapped in Al foil as well.  Both samples were collected fresh and injected into the PBS 
buffer within 3 min.  Taking the blood dilution into account, the final concentrations of 
GSH and EDTA were equal to that previously used in the GSNO calibration (i.e., 100 
μM GSH and 0.5 mM EDTA).  After the amperometric responses from both sensors 
reached steady-state, an aliquot from the 5 mM GSNO stock solution was added to the 
diluted blood to raise the GSNO concentration by 1 μM.  This standard addition method 
is used to calibrate the RSNO sensor in blood [43]. 
 
4.2.8. RSNO Determination in Rabbit Blood 
New Zealand White rabbits (2.5-3.2 kg body weight) were used in this study.  A 5 
mL of blood sample was drawn from rabbit carotid artery into a syringe with 5 U/mL 
sodium heparin (Baxter, Deerfield, IL).  To avoid potential loss of blood RSNO due to 
photo-decomposition, the blood sample was protected from light using aluminum foil 
covered syringe and immediately analyzed according to the procedure described above 
for pig blood RSNO determinations.   After the amperometric responses from both 
sensors reached steady state, the standard GSNO addition method was used to calculate 
the blood RSNO concentrations. 
 
4.2.9. Monitoring RSNO Levels in Rabbits under Extracorporeal Circulation 
The above blood RSNO determination was part of a biocompatibility study 
involving rabbits hooked to NO-generating extracorporeal circulation (ECC) loops (i.e., 
loops coated with plasticized PVC containing Cu-DTTCT catalyst) in an arterial/venous 
shunt model connecting the rabbit’s carotid artery and jugular vein.  The design and 
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biocompatibility evaluation of the NO-releasing version of the extracorporeal circuits 
based on DBHD/N2O2 has been described in detail previously [44].  In this study, rabbits 
under anesthesia were randomly assigned into three different categories: rabbits in Group 
I were hooked to Cu-based NO-generating ECC loops; in Group II, rabbits were hooked 
to control ECC loops that did not generate NO; the rabbits in Group III were just placed 
under anesthesia without ECC loops attached.  The baseline RSNO levels in all the 
rabbits, as well as the RSNO levels one hour after the surgical implantation of the ECC 
loops (or no loop as in Group III), were measured by the RSNO sensor following the 
procedure described above. 
 
4.2.10. RSNO Measurements for Pig Blood 
  The RSNO concentrations were also measured in porcine blood.  The pigs used in 
these experiments were implanted with NO-generating (i.e., Cu-DTTCT-containing 
polymer coated) or control vascular grafts.  In each animal, either two NO-generating or 
two control grafts were implanted between the femoral artery and vein.   The RSNO 
levels in arterial and venous blood were measured before and after the graft surgery 
following the same protocol used for the rabbit blood experiments described above.  In a 
follow-up study, the blood RSNO concentration was monitored periodically for up to 3 
weeks after surgery by obtaining blood samples from the jugular veins.  The samples 
were freshly collected and measured within 3 min following the same procedure used to 
assess rabbit blood. 
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4.3. Results and Discussion 
 
4.3.1. Sensitivity Towards NO and RSNO 
The RSNO sensor shown in Figure 1.3 is actually a modified NO sensor with an 
additional catalytic surface layer capable of decomposing RSNO to yield NO.  Therefore 
both, sensors exhibit amperometric responses toward the added NO standard as shown in 
Figure 4.2a.  The NO sensor was more sensitive towards NO compared with the RSNO 
sensor as it lacks the extra diffusion barrier imposed by the crosslinked RSePEI hydrogel 
layer.  However, upon addition of GSNO, only the RSNO sensor exhibits substantial 
amperometric response (see Figure 4.2b).  The RSNO sensor’s response to GSNO is 
totally reversible as the amperometric signal quickly returns to its original baseline when 
the GSNO solution is replaced by blank buffer.  During the RSNO calibration, a reducing 
agent such as GSH is necessary to produce the surface RSeH species needed to 
decompose RSNO [39], and the concentration of this reducing agent has been optimized 
in this study for the best RSNO sensitivity.  EDTA is also added to chelate any trace 
metal ion contaminants (e.g., Cu2+ or Fe2+) that might otherwise decompose RSNO in the 
presence of GSH.  As shown in Figure 4.2b, the NO sensor exhibits only slight increase 
in signal during the GSNO calibration.  This indicates that without the RSePEI catalyst, 
the self-decomposition of the RSNO species in the bulk solution is minimal.  The small 
current response from the NO sensor might come from the NO generated at the distal tip 
of the RSNO sensor (i.e., diffusion into the bulk solution from catalytic layer).  However, 
such ‘cross-talk’ between the two sensors is eliminated in actual blood measurements as 
the blood sample contains oxyhemoglobin, a very efficient scavenger of NO.  Such  
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Figure 4.2. Calibration curves of the RSNO and NO sensor for (a) NO in PBS buffer, and 
(b) GSNO in PBS buffer containing 100 μM GSH and 0.5 mM EDTA. 
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attributes are essential for the dual sensor set-up to reliably detect RSNOs in biological 
samples.  Unlike the previously reported Cu-based RSNO sensor [36], a significant 
improvement of the RSe-based RSNO sensor is its nearly equal sensitivity towards most 
LMW RSNOs encountered in blood [35], thus making it suitable to assess the overall 
concentration of all LMW RSNO species (e.g., GSNO, CysNO, etc.) present in blood.   
The RSe-catalyzed RSNO decomposition requires the presence of a reducing 
agent such as GSH or cysteine.  Therefore, the magnitude of RSNO sensor response to a 
given RSNO species depends not only on the RSNO concentration, but also on the type 
and concentration of reducing agent used.  The amperometric response of the RSNO 
sensor towards a given concentration of RSNO increases as more reducing agent is 
present.  However, results suggest (data not shown) that when the GSH concentration is > 
100 μM, the RSNO sensor’s sensitivity towards RSNO is not further enhanced by 
increasing concentrations of GSH.  Therefore, 100 μM GSH is used in both sensor 
calibration and actual blood measurement to provide sufficient reducing equivalents for 
RSNO decomposition and to eliminate the dependence of RSNO sensor signal on 
endogenous reducing agent concentrations in blood.  
It should be noted that the GSNO calibration is not used to calculate the final 
blood RSNO concentrations.  Rather it serves as indication of the proper functionality of 
the RSNO sensor.  The GSNO and NO calibrations of RSNO sensor in buffer reveals a 
ca. 10-fold sensitivity difference with the RSNO sensor being more ‘sensitive’ to NO 
than GSNO (i.e., the RSNO sensor showed similar total amperometric response to 100 
nM NO and 1 μM GSNO).  The reason is that for the GSNO measurement, only a 
fraction of the NO generated by the RSe-catalyzed GSNO decomposition can diffuse to 
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the electrode surface to be detected by the NO-sensitive electrode of the RSNO sensor.  
Nevertheless, this fraction appears to be constant within the concentration range of 
interest, as evidenced by the linear range of the GSNO response.   
As mentioned earlier, the amperometric responses of the RSNO sensor to various 
LMW RSNO species are similar when the same thiol species is used as the reducing 
agent (e.g., GSH or cysteine).  However, it should be noted that the sensor signal is 
dependent on the type of reducing thiol used, with cysteine usually yielding higher 
current response compared to GSH to detect the same RSNO concentration.  This is 
likely due to the smaller size of the cysteine molecule (vs. GSH), which diffuses more 
easily into the dialysis membrane and hence produces more reduced RSeH species within 
the RSePEI hydrogel layer for the decomposition of RSNO.  However, the choice of 
reducing agent is unlikely to affect the RSNO measurements in blood, since the reducing 
agent is expected to affect the amperometric signals from endogenous RSNOs and added 
GSNO standard to a similar extent. 
The current output of amperometric sensors is also dependent on temperature.  
Therefore, temperature control is critical for the accurate measurements of RSNO by the 
new electrochemical RSNO sensor.  To minimize delay in blood measurements, the 
temperature of the diluent buffer and the blood sample should be the same.  Thus the 
entire setup was thermostated at 34 ºC, a few degrees lower than the body temperature of 
animals, to adjust for the small temperature drop in the blood sample after it is drawn into 




4.3.2. AlbSNO Detection via Transnitrosation 
Due to the molecular weight cut-off of the outer dialysis membrane (50 kDa), 
high molecular weight (HMW) RSNO species such as S-nitrosoalbumin (66 kDa) or S-
nitrosohemoglobin (64 kDa) cannot diffuse through the membrane of the sensor to reach 
the crosslinked RSePEI hydrogel.  Therefore, the current RSNO sensor design cannot 
directly measure HMW RSNOs.  However, another mechanism known as transnitrosation 
exists where the nitroso group can be exchanged between an RSNO and a free thiol [45].  
Although the transnitrosation process normally favors the formation of HMW RSNOs 
under physiological conditions [8], it is still possible to form a substantial amount of 
LMW RSNO by reacting HMW RSNO with excess (e.g., 100 μM) of LMW thiols (e.g., 
GSH or cysteine).  In this case, the added GSH or cysteine acts as both a reducing agent 
to produce the needed RSeH surface catalyst and a transnitrosating agent to accept the 
nitrosonium ion (NO+) to form the corresponding LMW RSNO.  The transnitrosation 
efficiency is a function of the reducing agent concentration, but increasing GSH/cysteine 
concentrations can only improve the yield of LMW RSNOs to a limit.  For example, 100 
μM cysteine is the optimal concentration to obtain the maximum detectable current from 
the transnitrosation of AlbSNO.  Higher (e.g., 200 or 500 μM) cysteine concentrations 
result in lower amounts of CysNO detected by the RSNO sensor.  Since CysNO is much 
less stable compared to most LMW RSNOs (e.g., GSNO or S-nitroso-N-acetyl-
penicillamine, SNAP), this is likely due to the auto-decomposition of CysNO in high 
concentrations of reducing agent [10]. 
The detection of AlbSNO in 100 μM cysteine yielded ~ 84% equivalent to the 
response of the same sensor to CysNO over a much longer period of time (i.e., 20-30 
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min, see Figure 4.3).  The transnitrosation efficiency of 100 μM GSH was lower (c.a. 
60%).  This is probably because of the weaker reducing power of GSH and its larger size, 
resulting in slower diffusion through the dialysis membrane.  As discussed earlier, the 
RSNO sensor response depends on the thiol species.  Therefore, it is worth mentioning 
that the percentage of AlbSNO recovery reported herein is calculated on the basis of 
corresponding RSNO calibration using its parent thiol as the reducing equivalent (i.e., 
GSNO/GSH or CysNO/Cysteine).  The prolonged response time towards AlbSNO 
compared to LMW RSNOs also suggests the involvement of a slow transnitrosation 
reaction, which must occur prior to the diffusion of RSNO through the outer dialysis 
membrane.   
Although it takes much longer to reach the steady-state current in transnitrosation 
measurements, it is unlikely that the amperometric signal of the RSNO sensor in the 
presence of AlbSNO originates from the auto-decomposition of AlbSNO in the presence 
of free thiols.  To check the background NO signal during transnitrosation, only the NO 
sensor was placed in a solution containing same concentrations of AlbSNO and cysteine.  
Over the same time window, less than 5% of NO equivalents to the added AlbSNO were 
detected by the NO sensor.  This is further supported by the chemiluminescence NO 
measurement—only a negligible amount of NO (2-4 ppb) was detected when the same 
concentrations of AlbSNO, EDTA and reducing agent were mixed together in the 
absence of RSePEI catalyst. 
 
4.3.3. Matrix Effects in Biological Fluids 









Figure 4.3. The responses of a RSNO sensor to CysNO and AlbSNO in PBS containing 
100 μM cysteine and 0.5 mM EDTA. 
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The successful translation of calibrations performed in buffer to that in plasma is 
essential for the validation of RSNO measurements in blood.  Towards this goal, the 
RSNO sensor response to GSNO was also evaluated in a 1:2 dilution of plasma into PBS 
(see Figure 4.4a).  The presence of plasma did not affect the calibration towards LMW 
RSNO species.  Therefore, it can be concluded that the non-specific adsorption of plasma 
proteins and platelets, if any, does not alter the diffusion of RSNOs and reducing agent to 
the RSePEI hydrogel layer behind the dialysis membrane.   
 
4.3.3.2. Free Hemoglobin 
It is well known that oxyhemoglobin is a potent scavenger of NO to yield 
methemoglobin and nitrate [46], and that deoxyhemoglobin acts as nitrite reductase to 
produce NO [47].  In the current sensor configuration, hemoglobin cannot diffuse through 
the dialysis membrane to directly react with the NO produced by the RSePEI-catalyzed 
RSNO decomposition.  However, physiological levels [48] of free hemoglobin can still 
affect the RSNO sensor response.  As shown in Figure 4.4b, the presence of free 
oxyhemoglobin reduces the GSNO signal, especially at low GSNO concentrations.  In 
another experiment, ~ 20% decrease in amperometric response was observed when free 
hemoglobin was added after the steady-state current was reached in the presence of 4 μM 
GSNO.  This is likely attributed to the role of oxyhemoglobin as an NO ‘sink’ on the 
outside of the dialysis membrane.  The NO produced within the thin catalyst layer 
between the dialysis and gas permeable membrane can diffuse in all directions.  Under 
normal conditions, the fraction of NO that diffuses to the surface of the gas-sensing 
electrode to yield the amperometric signal is constant.  When hemoglobin is present in  
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Figure 4.4.  GSNO calibrations in biological matrices.  (a) in PBS and 1:2 diluted rabbit 
plasma; (b) in PBS with and without 15 mg/dL oxyhemoglobin. 
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the solution outside the dialysis membrane, it scavenges NO, lowering the NO 
concentration outside the dialysis membrane and therefore creating a steeper 
concentration gradient.  As a result, more NO diffuses to the outside of the dialysis 
membrane, creating a lower steady-state NO level within the RSePEI layer.  It can be 
speculated that such scavenging effects would be similar to both endogenous RSNOs and 
the GSNO added during blood measurements.  Thus, this effect of hemoglobin, as well as 
other possible NO scavengers in blood, should be taken into account in the final blood 
measurement via the proposed standard addition method.  After the amperometric 
response from blood samples reaches a steady-state, one or more aliquots of a GSNO 
standard with known concentration was spiked into the diluted blood samples to correct 
for the scavenger and viscosity effect in blood (see below, Figure 4.5a).  The calibration 
obtained from the standard addition is used instead of the prior GSNO calibration in 
buffer to calculate the final concentration of RSNO in blood samples.  
 
4.3.4. Photo-Instability of RSNOs 
The literature reported values of endogenous RSNO concentrations range from tens 
of nM to a few μM [29].  One important reason behind these variable values for 
endogenous RSNO concentrations is the labile nature of the RSNO compounds, which 
can easily be decomposed by heat, light and metal ions [10].  For the same reason, it is 
believed that sample handling is critical for proper determination of endogenous RSNO 
levels.  However, most current techniques for blood RSNO measurements require the 
separation of blood by centrifugation and subsequent treatments of plasma samples with 
various reagents [26, 49].  During these processes, the exposure to light is difficult to 
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completely eliminate.  The advantage of the electrochemical RSNO sensor is the minimal 
sample preparation: the blood RSNOs can be measured immediately in fresh whole blood 
without the need for any plasma separation.  Therefore, the artifacts that might be 
introduced during the sample handling steps can be avoided.  In addition, this unique 
advantage of the RSNO sensor also offers a chance to study in detail the effects of blood 
exposure to external variables, such as light, on the stability of endogenous RSNOs. 
Despite the general perception that the absorbance of blood is so large that it 
protects the endogenous species from photodecomposition, it was discovered in this 
research that for fresh blood, very little amperometric response could be obtained if the 
samples had not been well protected from light, even over a very short period of time 
during the drawing of the blood sample.  To study the effect of light exposure on the 
stability of endogenous RSNOs, an experiment was designed to draw blood through a 
butterfly needle tubing either with or without protection from light.  The butterfly needle 
contains a plastic tube 12 inch in length and ca. 1 mm in i.d.  It is connected to a 
heparinized 5 mL syringe that is always protected from light via Aluminum foil.  During 
blood collection, it normally takes less than 20 sec for blood to pass through the butterfly 
tube.  Figure 4.5a shows representative RSNO sensor responses to the venous blood from 
the same animal (pig) by both the covered and exposed sampling method.  Using the 
standard addition method, which is discussed in more detail below, the RSNO 
concentration in this particular experiment was determined as 1.45 μM when the entire 
path of blood was protected from light. However, when the butterfly tube was not 
protected from light, the measured RSNO level dropped to 0.40 μM (i.e., 27.6%).  It can 



































Figure 4.5. RSNO concentrations measured by exposed and covered sampling. (a) 
Amperometric responses from the RSNO sensors to blood followed by a 
standard addition of 3 μM GSNO; (b) RSNO concentrations measured in 
eight animals. 
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Therefore, the only plausible explanation for the decreased blood signal is the 
photodecomposition of RSNO during exposed sampling.  A total of 8 sets of 
measurements of this type were performed in this manner with 6 pigs and a drop of 
RSNO level in the exposed blood samples was always observed.  The results are 
summarized in Figure 4.5b with the RSNO levels from covered samples normalized to 
100%.  It can be seen that the RSNO levels dropped substantially in exposed blood 
samples, to only 23.6 ±7.2 % of that obtained from covered samples.  This suggests that 
exposure to light, though brief, has a significant impact on the RSNOs in blood samples.  
The light effect can be expected to be much more significant on plasma samples, as they 
lack the ‘shield’ from light offered by red blood cells.  This might also explain why some 
researchers found the LMW RSNO species ‘undetectable’ in blood samples [16].  This 
research emphasizes the importance of sample handling in RSNO determination and also 
helps to elucidate the controversy over endogenous RSNO levels. 
 
4.3.5. RSNO Determinations in Rabbit Whole Blood 
The widely used triiodide assay method in RSNO quantification requires to 
centrifuge blood first and then to make three separate measurements of the obtained 
plasma sample in order to differentiate nitrite, RSNO and other nitroso- species such as 
N-nitrosamine and iron-nitrosyl compounds [26].  The merit of the RSNO sensor 
described herein is its specificity towards RSNO species, which can be harnessed to 
measure RSNOs directly in whole blood without the need for centrifugation or other 
subsequent treatments of plasma samples.  Our studies have proved that the RSe-based 
catalyst is highly selective for RSNOs against other NO derivatives commonly 
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encountered in blood.  No amperometric responses are observed for up to 2 mM nitrite or 
300 μM N-nitrosamine (N-nitroso-L-proline) [50].  Therefore, the contribution to the 
amperometric signals from such compounds in the blood sample would be negligible.  
Blood is an extremely complicated matrix containing low levels of NO as well as 
other volatile species (e.g., ammonia, hydrogen peroxide, etc.) that might be oxidized at 
the applied potential used in the RSNO sensor.  This demands the use of a control NO 
sensor, which is almost identical to the RSNO sensor except it does not possess the 
RSePEI catalyst layer.  The signal from the control sensor can be used to correct for the 
contributions from potential interfering species.  Both the NO sensor and the RSNO 
sensor must be calibrated with NO first, thus the difference in the measured current from 
blood samples reflects the additional amount of NO being produced at the electrode 
surface due only to the Se-catalyzed decomposition of RSNOs.  Based on the calibrations 
for NO and standard addition of GSNO into diluted blood samples, this additional NO 
signal can be translated into RSNO concentrations in blood. 
A representative blood RSNO measurement is shown in Figure 4.6, where the 
amperometric responses from both sensors have been converted into the equivalent 
concentrations of NO.  After the blood RSNO signal stabilizes, 3 μM GSNO is added to 
the diluted blood to implement a standard addition method for quantifying total RSNO 
levels.  The RSNO concentrations in blood are calculated according to Equation 4.1: 
 
[RSNO]whole blood = DF*([NO]RSNO Sensor – [NO]NO Sensor)*SRRSNO Sensor (4.1) 
 









Figure 4.6.  Rabbit blood RSNO measurement by the RSNO/NO sensor pair followed by 
a standard addition of 3 μM GSNO. 
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is the NO equivalent concentrations (based on previous calibration of NO) measured by 
the RSNO and NO sensors, respectively; SRRSNO Sensor refers to the sensitivity ratio 
between GSNO and NO for the RSNO sensor.  This sensitivity ratio is obtained by 
dividing the RSNO sensor sensitivity towards GSNO in diluted blood (based on standard 
addition) by that towards NO in buffer. 
It should be noted that hematocrit (Hct) is not taken into account in the above 
equation to calculate RSNO levels, since the effect of Hct on endogenous RSNOs is still 
unclear.  Indeed, there is even a lack of consensus thus far regarding the levels of S-
nitrosohemoglobin within red blood cells [51, 52].  Hct is an important parameter in 
clinical diagnostics to obtain the concentrations of analytes in plasma versus those in 
whole blood [53].  However, it is not yet clear whether LMW RSNOs can diffuse freely 
into and from the red blood cells (i.e., evenly distributed in whole blood).  All the results 
reported herein are based on the assumption that RSNO concentrations in plasma and red 
blood cells are the same, which requires further experimental validation.  In case this 
assumption is not valid, a correction for Hct needs to be made, resulting in Equation 4.2: 
 
[RSNO]plasma = (DF-Hct%)*([NO]RSNO Sensor – [NO]NO Sensor)*SRRSNO Sensor /(1-Hct%)  (4.2) 
 
The effect of Hct should also be considered in obtaining SRRSNO Sensor, since the added 
RSNO standard is distributed in the volume of diluted blood minus that occupied by the 
red blood cells. 
Using this analytical approach (no Hct correction), the RSNO concentrations in a 
group of 32 rabbits were determined to be 3.04±1.93 μM.  The normal endogenous total 
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RSNO concentration has been the spotlight of controversy over the past decade [29] due 
to its labile nature and the various analytical methods employed in its detection.  
Interestingly, this study reveals that even by the same analytical method with minimal 
sample preparation, substantial variations of RSNO concentration still exist among 
individual animals of the same species.  The RSNO concentrations span over a range 
from 0.37 μM to 7.44 μM with the majority (18 out of 32) falling between 1-3 μM.   A 
plot of the distribution of RSNO levels is shown in Figure 4.7.  It should be noted that the 
sensitivity of the RSNO sensor is not compromised after repeated exposure to fresh 
blood. 
Previous reports suggested that the majority of RSNOs in circulating blood exist in the 
form of AlbSNO [54].  As discussed earlier, the RSNO sensor is capable of detecting 
HMW RSNOs such as AlbSNO at near quantitative yield through a transitrosation 
reaction with added thiol/reducing agent.  However, such reaction takes much longer to 
reach steady-state current in buffer as compared to the detection of their LMW 
counterparts (i.e., 20-30 min vs. 4-5 min).  Indeed, the equilibration time for the RSNO 
sensor to reach steady-state current in blood samples (as well as for subsequent standard 
RSNO additions) is even shorter, typically 2-4 min.  Given this short equilibration time, 
the contribution of AlbSNO to the detected signal should be small.  Therefore, it is likely 
that the RSNO signal measured with the new RSNO sensor comes predominantly from 
LMW RSNO species in the blood.  Research is underway in this laboratory to develop 
new RSNO sensors that have similar sensitivity and response times towards both LMW 





























































































4.3.6. Change of RSNO Levels in Rabbits under ECC 
Since RSNOs are used as the endogenous substrates for newly-developed NO-
generating polymers [55], the change of endogenous RSNO concentrations may serve as 
an indication of the function of NO-generating polymers.  If the RSNO is consumed by 
the NO-generating polymers at a rate faster than the rate of its biosynthesis in the blood, a 
gradual decline in endogenous RSNO level can be expected.  Obviously, the rate of 
RSNO consumption is dependent on both the surface area of NO-generating polymer and 
the volume of circulating blood.     
The ECC loops used in this study have a surface of ca. 60 cm2 in contact with 
flowing blood and rabbit blood volume is normally 70 mL/kg of body weight [56].  The 
rabbit blood is passed through a loop with relatively large surface area, and thus the 
consumption of RSNO is expected to be very fast if the loop has been coated with NO-
generating materials.  On the other hand, the endogenous RSNO levels should maintain 
consistent if the ECC loop is coated with control polymers that do not consume RSNOs, 
or even there is no ECC loop attached to the animal at all.  The change of blood RSNO 
levels over the first hour for rabbits in the ECC study is plotted in Figure 4.8.  RSNO 
levels at Hour 0 are the baseline values and the RSNO levels at Hour 1 have all been 
normalized to the relative percentage of their respective baseline.  After 1 h circulation, 
the blood RSNO levels in rabbits receiving NO-generating ECC loops drop to 27.3±
14.2% (N=10) of the baseline at Hour 0.  But after 1 h, the RSNO levels in rabbits 
attached to control circuits or no circuits at all are still maintained at 98.9±11.5% (N=7) 
and 94.9±10.3% (N=5) respectively.  It can be seen that the NO-generating ECC loops 
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hour.  This result also suggests that supplementation of RSNO to rabbits might be 
necessary to achieve sustainable NO-generation in ECC operations, which normally last 
4-6 h.  
 
4.3.7. RSNO Determinations in Pig Blood 
Unlike ECC, in some implantable applications of NO-generating polymers such 
as intravascular sensors or vascular grafts, the contact surface is much smaller and hence 
the rate of RSNO consumption should be much slower.  It has also been reported that a 
concentration gradient of S-nitrosohemoglobin exists between arterial and venous blood 
[57].  Therefore, in this work, we applied the new RSNO sensor method described above 
to: 1) examine the change of endogenous RSNO levels, if any, over time when NO-
generating vascular grafts are implanted in vivo; 2) measure the RSNO concentrations of 
both arterial and venous blood from the same animal to determine if there is any 
concentration gradient. 
The venous RSNO levels at three time points were monitored, including the 
RSNO baseline obtained right before the surgical implantation of vascular grafts and the 
RSNO concentrations 1 week and 3 weeks after the surgery.  The baseline RSNO levels 
in venous pig blood were found to range from 0.6 to 2.7 μM (1.57±0.75 μM, N=9) and 
the changes in RSNO were normalized with respect to the baseline values (i.e., baseline = 
100%).  In pigs with NO-generating grafts, the venous RSNO levels dropped to 77.0±
2.2 % (N=2) after 1 week and further decreased to 54.1±11.7% by the end of 3 weeks.  
On the other hand, the RSNO levels in pigs with control grafts remained relatively 
constant, being 102.6±2.1% (N=2) after 1 week and 95.3±27.6% (N=3) after 3 weeks.  
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It can be concluded from these preliminary data that the presence of NO-generating 
catalyst in vivo gradually consumes the endogenous RSNO species.  This also serves as 
indirect evidence that the NO-generating polymers are functioning in vivo.  The overall 
change of RSNO concentration results from the different rates of RSNO consumption by 
NO-generating polymers and the rate of RSNO production by the animal.  It is therefore 
dependent on the ratio of polymer surface area to blood volume.  These vascular grafts 
are 6-8 cm in length and 6 mm in i.d. (surface area ~ 12-15 cm2), with the NO-generating 
polymers coated on the inside.  Such a surface area lies in between that of intravascular 
sensors and the surface area of coatings on extracorporeal circuits.  It can then be 
reasonably speculated that the consumption of RSNO would be much slower for NO-
generating intravascular sensors, while much faster in the case of NO-generating 
extracorporeal circuits.   
The RSNO concentrations in arterial and venous blood were determined in 3 pigs, 
with the arterial RSNO levels found to be 94.6±1.3% of those in the veins.  Hence, there 





RSNO species play important roles in the metabolism of NO and they act directly 
in regulating platelet activity and endothelial function.  The measurement of endogenous 
RSNOs is a popular yet controversial topic.  RSNOs are labile species, but currently 
available techniques to measure RSNOs in blood require methods and associated 
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treatments which may introduce substantial artifacts.  Using a newly developed RSePEI-
based amperometric RSNO sensor, the endogenous RSNO (predominantly LMW 
RSNOs) concentrations in animal (rabbits and pigs) blood can be determined with 
minimal sample preparation.  The sensor results indicate that substantial variations in 
endogenous RSNO concentrations exist even within the same animal species.  The photo-
decomposition of RSNOs in blood during the sample collection stage was also examined.  
The results suggest that even a short exposure to ambient light has detrimental effects on 
the accuracy in the determination of endogenous RSNOs.  These findings emphasize the 
importance of proper sample handling in obtaining reliable values of endogenous RSNO 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
5.1. Summary of Results for Dissertation Research 
 
Nitric oxide has been found to be a potent inhibitor of platelet activation and 
adhesion, as well as an effective vasodilator.  Polymers that can continuously release low 
levels of NO in vivo could potentially enhance the biocompatibility of blood-contacting 
medical devices such as intravascular sensors [1, 2], vascular grafts [3], extracorporeal 
circuits [4] and hemodialysis filters [5].  In this dissertation research, efforts have been 
made to develop new strategies to evaluate the biocompatibility of the NO-
releasing/generating polymeric materials both in vitro and in vivo.  In addition, due to the 
critical role of S-nitrosothiols (RSNOs) in generating NO at the polymer/blood interface, 
their endogenous concentrations have also been determined in a number of animals via a 
novel RSePEI-based electrochemical RSNO sensor.   
In Chapter 2, an in vitro platelet adhesion assay was developed via the quantification 
of platelet lactate dehydrogenase (LDH) content to study the in vitro biocompatibility of 
NO-releasing/generating polymeric materials.  Through the LDH assay, it was discovered 
that increasing levels of NO released from plasticized poly(vinyl chloride) films which 
were doped with DBHD/N2O2 could inhibit the adhesion of rabbit platelets to the surface 
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of such polymers.  The highest NO-release flux studied, 7.05 ×10-10 mol cm-2 min-1, 
reduced the adhesion of platelets by as much as 78.9% compared to the control polymers 
that did not release NO (from 14.0 (±2.1) ×105 cells cm-2 to 2.96 (±0.18) ×105 cells cm-2).  
This work was the first quantitative in vitro assay that proved the enhanced 
biocompatibility of NO-releasing polymers.  The new LDH-based method might 
potentially serve as a preliminary biocompatibility screening method for new NO-
releasing materials that will emerge in the future.   
 The LDH assay for NO-generating polymers, however, encountered serious 
challenges.  Addition of 5 μM GSNO to plasma samples reduced platelet adhesion.  
Further, the presence of an NO-generating Cu-DTTCT catalyst did not enhance the 
biocompatibility when compared to control polymers.  The reasons for this result may 
involve the rapid decomposition of RSNOs by the NO-generating polymers, which was 
not commensurate with the duration of PRP incubation, or the photo-instability of 
RSNOs in plasma.  Further investigation is required to decipher this observation. 
 The ideal biocompatibility evaluation methodology for NO-generating polymers 
is via in vivo studies as a continuous supply of RSNOs will be provided by the flowing 
blood.  A proof-of-concept experiment on the enhanced in vivo biocompatibility of NO-
generating polymers coated on the surfaces of intravascular sensors is described in 
Chapter 3.  The NO-generating coatings were created by impregnating metallic Cu0 
particles of different sizes (i.e., 80 nm or 3 μm) into polymer coatings made of either 
hydrophobic polyurethane (Tecoflex SG80A, for 80 nm Cu0 particles) or a mixture of 
hydrophilic polyurethane (Tecophilic SP-60-D-60) and silicone rubber (RTV-3140, for 3 
μm Cu0 particles).  The coatings were applied on the surface of a catheter-type, Clark-
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style amperometric oxygen sensors for intravascular implantation.  Sensors with either 
NO-generating coatings or control coatings (polymers without doped Cu0 particles) were 
implanted in porcine carotid and femoral arteries and used for continuous monitoring of 
blood PO2 levels for up to 20 h.  The data suggest that more statistically reliable results 
are obtained from the NO-generating sensors, with the average of measured PO2 values 
falling within 95% confidence interval of the ‘true values’ read by bench-top blood gas 
analyzer from discrete blood samples drawn from the animals.  The control sensors, 
however, started to deviate beyond the 95% confidence interval after 10-15 h of 
implantation.  After each experiment, the sensors were carefully removed and examined 
via the LDH assay for thrombus formation on the surfaces.  This surface examination 
revealed similar results.  Although thrombus was still found on ~ 20% of NO-generating 
sensors evaluated, the average degree of thrombosis was much less than that on the 
control sensors, which also had a more frequent occurrence of thrombus (~ 80% of the 
time).   This research demonstrated that in situ generation of NO at the polymer/blood 
interface could be utilized to enhance the biocompatibility of implanted medical devices.   
 Since RSNOs are used as the substrates to generate NO in vivo, their 
concentrations are an important factor in determining whether sufficient NO can be 
generated at the polymer/blood interface in order to maintain thromboresistance.  
Consequently, the occasional thrombus formation on the NO-generating sensors 
examined in Chapter 3 initiated the investigation into the possible variations of 
endogenous RSNO concentrations in animal blood.  Besides the use as biomaterials, the 
NO-generating polymers can also be employed in detecting RSNOs via the catalytic 
conversion of RSNOs into NO.  Indeed, electrochemical RSNO sensors have already 
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been designed by modifying amperometric NO sensors with additional catalytic 
membranes that convert RSNO into NO [6, 7].  The RSePEI-based RSNO sensor has the 
advantage of being almost equally sensitive to all LMW RSNOs and is thus well suited to 
assess the overall concentrations of LMW RSNOs in blood.  Further characterization of 
such an RSNO sensor based on immobilized RSePEI catalyst, and its applications in 
determining the endogenous RSNO concentrations in animal (i.e., rabbits and pigs) 
blood, were the major focus of Chapter 4.   
In this study, an average blood concentration of 3.04 ± 1.93 μM RSNOs 
(predominantly LMW RSNOs) was determined from a group of 32 rabbits.  Considerable 
variations existed in the measured concentrations of endogenous RSNOs, ranging from 
0.37 μM to 7.44 μM.  Unlike other methodologies employed in RSNO measurements, the 
electrochemical RSNO sensor requires virtually no sample preparation and the delay 
between blood collection and analysis can be minimized.  This unique advantage offered 
the chance to study other factors during the sampling stage that may affect the accurate 
determination of RSNO concentrations.  Specifically, the photo-decomposition of RSNO 
when blood was passed through a plastic tube during sample collection was studied by 
either completely covering the tube with Aluminum foil or allowing the tube to be 
exposed to light.  Assuming the covered sample preserved 100% of all RSNOs, the 
amount of RSNOs remaining in the exposed samples was only 23.6 ±7.2 % (N=8).  This 
study showed that even very brief exposure to light could have a detrimental effect on the 
levels of RSNOs in blood.  Therefore, the proper handling of blood samples is critical for 
the accurate measurement of RSNOs.  In addition, it also suggests greater potential 
biomedical applications of the electrochemical RSNO sensors. 
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5.2. Future Directions 
 
This dissertation research demonstrated the potential of NO-releasing/generating 
materials in enhancing biocompatibility both in vitro and in vivo.  However, further 
investigation is still needed to develop more biocompatible materials/devices in the 
future. 
 
5.2.1. In Vitro Biocompatibility Assays 
The LDH assay described in Chapter 2 is capable of providing quantitative results 
on platelet adhesion.  However, it merely counts the number of platelets regardless of 
their state of activation.  In many biomedical applications, the degree of platelet 
activation is an important piece of information, as activated platelets are key to initiate 
the coagulation cascade, resulting in thrombosis [8].  Therefore, it is necessary to develop 
an in vitro assay to study platelet activation on NO-releasing/generating materials 
surfaces.   
P-Selectin (CD62P), a 140 KDa glycoprotein, is a component of the alpha granule 
membrane and is expressed at the surface of platelets upon activation [9].  It is regarded 
by many as a marker for platelet activation [10, 11].  Previous reports have shown that an 
NO donor, S-nitroso-N-acetyl-penicillamine (SNAP), could inhibit thrombin-induced 
platelet activation as determined via an enzyme-linked immunosorbent assay (ELISA) for 
P-selectin [12].  In the future, it may be possible to design a similar enzyme 
immunoassay for P-selectin to study platelet activation on the surface of NO-
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releasing/generating polymeric films.  It should be noted, however, that the locally 
released NO at the polymer surface might alter the activity of some enzymes, such as 
horseradish peroxidase (HRP) often used in an ELISA-type assay.  In that case, the 
activities of the enzyme labels on the antibodies bound to NO-releasing/generating 
polymer surfaces might be considerably different from those of the enzymes on control 
polymer surfaces.  If so, alternative enzyme labels should be sought, or it might be 
possible to use the soluble P-selectin in plasma [13, 14] as the platelet activation marker 
and measure it in a similar manner to that in the LDH assay. 
 
5.2.2. In Vivo Evaluation of NO-Releasing/Generating Polymers 
The NO-generating polymers based on organoselenium catalysts appear 
promising for in vivo applications.  A layer-by-layer deposition method of RSePEI onto 
silicone rubber surfaces is a potential candidate for the next set of in vivo studies via the 
intravascular oxygen sensor model.  Nevertheless, challenge still remains for the in vivo 
application of RSe-based NO generation in terms of its catalytic efficiency.  When 
compared to Cu-based NO generation, organoselenium catalysts require much higher 
RSNO concentrations (i.e., ~ 50 μM, well beyond the endogenous RSNO levels) to 
generate NO fluxes similar to those produced by the human endothelium.  One approach 
to increase the flux levels generated by the RSe-based catalysts might be the creation of a 
brush-type structure of the SePEI polymer chain on the polymer surface, such as that has 
been commercially used on CorlineTM surfaces for heparin immobilization [15], in order 
to maximize the surface density of the catalysts. 
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As discussed in Chapter 1, needle-type subcutaneous sensors can be used for 
minimally invasive glucose monitoring in diabetic patients.  The schematic of a needle-
type NO-releasing glucose sensor based on the NO donor, DBHD/N2O2 [3], is shown in 
Figure 5.1.  The biocompatibility of this glucose sensor may also be evaluated in the 
porcine artery model once it has been more thoroughly characterized in vitro.  It should 
be noted that due to their smaller dimension, thrombus is less likely to form on the 
control glucose sensors compared to the control oxygen sensors.  Thrombosis may be 
induced by a change in blood flow. But the small diameter of the needle-type sensor has 
little impact on hemodynamics as it will not significantly change the flow of blood 
around it.  In this case, experimental conditions need to be optimized to create contrast 
between the NO-releasing and control needle sensors to promote thrombosis. 
 
5.2.3. Electrochemical RSNO Sensors 
Several questions need to be addressed in the future development of the 
amperometric RSNO sensors.  First and foremost is the detection of HMW endogenous 
RSNOs such as AlbSNO, since they have been suggested to be the major RSNO 
reservoirs in vivo.  In order to determine the overall RSNO concentrations in blood, an 
RSNO sensor with similar sensitivities and response times towards both LMW and HMW 
is required.  Efforts have been made in this lab to create catalytic membranes from 
commercial dialysis membranes to improve HMW RSNO sensitivities.  It may also be 
possible to immobilize Se-based catalysts directly on the surfaces of gas-permeable 





































The second question is the effect of red blood cells.  Many researchers are 
interested in the S-nitrosohemoglobin (Hb-SNO) concentrations within the red blood 
cells.  The triiodide assay, which measures the NO liberated from various nitroso 
compounds in plasma samples via reductive chemiluminescence with acidified 
iodide/iodine solution, has traditionally been employed in such studies.  But it is an area 
of intense debate as three separate measurements are necessary to differentiate nitrite, 
RSNO and other nitroso-compounds [16-20].  The RSNO sensor methodology is believed 
to be advantageous in blood RSNO determinations.  It will be exciting if the RSNO 
sensor can also be used to measure Hb-SNO in the red blood cells.  However, precautions 
need to be taken since hemoglobin is a very complicated molecule and serves multiple 
roles in the reactions with NO and/or RSNO [16, 21].  In addition to being the acceptor of 
nitroso- groups, hemoglobin can react with NO or RSNO to form iron-nitrosyl 
compounds [22], and oxyhemoglobin can scavenge NO to form methemoglobin and 
nitrate [23].  All of these reactions need to be taken into account when measuring Hb-
SNO within red blood cells.  Another concern about the red cells is the hematocrit effect.  
It is not yet clear whether the RSNO concentrations in plasma and red cells are equal.  In 
other words, can the RSNOs (either endogenous or added during standard addition) 
rapidly diffuse into the red blood cells to achieve a uniform concentration in whole 
blood?  This question needs to be addressed before any statements of ‘plasma’ or ‘whole 
blood’ concentrations of RSNO can be made. 
Last but not least, is the elimination of interferences.  The RSNO sensor is highly 
selective against nitrite and other nitroso- species that interfere with other RSNO 
detection methodologies.  The simultaneous use of an NO sensor also helps to reduce the 
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contribution from interfering endogenous species such as ammonia.  However, the RSNO 
sensor is still subject to its own interference problem, most notably a background current 
from high concentrations of reduced thiols.  An increase in baseline current was often 
observed after the addition of GSH or cysteine.   The identity of this electroactive species 
produced within the catalytic layer by reduced thiols is largely unknown, although it is 
suspected to be hydrogen peroxide produced by the oxidation of the thiols in the presence 
of oxygen [24].  Further research is needed to investigate the origin and nature of this 
unwanted signal in order to prepare more reliable RSNO sensors. 
 
5.2.4. The Future towards an ‘Artificial Endothelium’ 
To date, the functionality of implantable medical devices such as sensors is still 
hampered by the adverse biological responses.  Numerous attempts have been made to 
address the physicochemical properties of the materials surface for the development of 
biocompatible sensors [25].  As discussed in previous chapters, it has been recently 
shown that the local release/generation of biologically active species such as NO is 
capable of reducing thrombus formation on intravascular sensors.  However, NO alone is 
unlikely to be the solution to the entire biocompatibility problem.  Indeed, the vascular 
endothelium is a perfectly non-thrombogenic surface due to a number of molecules 
working synergistically to maintain vascular homeostasis.  A biomimetic approach to 
create an ‘artificial endothelium’ will likely provide the most promising route to the 
development of truly biocompatible sensors.  NO-releasing/generating polymers are the 
first step in this direction.  Further, surface immobilization of heparin and 
thrombomodulin, used in conjunction with continuous release of a variety of naturally 
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occurring antithrombogenic species (including prostacyclin), may enable the implanted 
devices to exhibit even greater biocompatibility than NO release/generation alone.  A 
dual-functional polymeric coating with surface-immobilized active heparin and NO-
release has recently been reported [26].  In addition, it has been found that surface-bound 
thrombomodulin and heparin on NO-releasing polymers retained their biological function 
and might be a promising candidate for future development of more biocompatible 
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